Protocol Title: Implementing the Los Angeles Barber-Pharmacist 
Model of Hypertension Management in Nashville
Protocol Date: 2/25/[ADDRESS_242089] # [STUDY_ID_REMOVED]
   
  
Implementing the Los Angeles Barber -Pharmacist 
Model of  HYPERTENSION MANAGEMENT  
IN NASHVILLE  
 
 
A Barber -Pharmacist -Physician Partnership  for  
Blood Pressure Management  
 
 
Principal Investigator:  
[INVESTIGATOR_202874], MD  
 
 
Department:  
Internal Medicine  
 
 
Institut ion: 
Vanderbilt University Medical Center (VUMC)  
 
 
Study Support Provided By:  
[CONTACT_60625] (NIH)  grant: UL1TR001881 -03S2  
 
 
Contact:  
 
 
[CONTACT_202927],  
[PHONE_4374]  
[EMAIL_4000]  
 
 
Version 2.0  
2/25/2020  
 
  

 
Protocol Version 2.0  Page 2 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  TABLE OF CONTENTS  
 
Abbreviations  ................................ ................................ ................................ ............................  4 
Amendments  ................................ ................................ ................................ .............................  5 
Study Summary  ................................ ................................ ................................ .........................  6 
Background  ................................ ................................ ................................ ...............................  7 
Study Objective and Aim  ................................ ................................ ................................ ..........  8 
Study Design and Overview  ................................ ................................ ................................ ..... 8 
Participant Selection and Withdrawal  ................................ ................................ ......................  8 
Study Intervention  ................................ ................................ ................................ ..................  10 
Ascertainment of Outcomes   ................................ ................................ ................................ . 11 
Study Procedures and Visits  ................................ ................................ ................................ .. 13 
Statistical Analysis Plan  ................................ ................................ ................................ .........  14 
Adverse Events  ................................ ................................ ................................ .......................  16 
Data Management  ................................ ................................ ................................ ...................  18 
Study Oversight  ................................ ................................ ................................ ......................  19 
References  ................................ ................................ ................................ ..............................  20 
Appendix 1: Participating VUMC Researchers  ................................ ................................ ..... 22 
Appendix 2: Study Schedule  ................................ ................................ ................................ .. 23 
Appendix 3: Clinical Pharmacist Collaborative Practice Agreement  ................................ .. 24 
Appendix 4: Tennessee State Pharmacy Law  ................................ ................................ ....... 35 
Appendix 5: Study Hypertension Algorithm (standard of care)  ................................ ...........  37 
Appendix 6: Study Forms, Materials, and Surveys  ................................ ...............................  41 
6A: Barber shop/Owner  Letter of Collaboration  ................................ .........................  41 
6B.1: Screening Questionnaire 1  ................................ ................................ ................  43 
6B.2: Screening Questionnaire 2  ................................ ................................ ................  54 
6B.3: 3 -Month Telephone Survey  ................................ ................................ ...............  73 
6B.4: 6 -Month Visit Survey  ................................ ................................ .........................  77 
6B.5: Barber Exit Interviewâ€¦â€¦â€¦.â€¦â€¦â€¦.â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..9 2 
6C: Blood pressure Information Card ................................ ................................ ........  93 
6D: Template Pharmacist Note  ................................ ................................ ...................  94 
6E: Adverse Event Form  ................................ ................................ .............................  97 
6F: Template Letter to Physician â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦ .....99 
6G: Participant Treatment Report â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..1 01    
Appendix 7: Data Safety Monitoring Committee Plan/Serious Adverse Event Forms  .... 103 
 
Protocol Version 2.0  Page 3 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Appendix 8: Relevant Definitions of Safety Terms per NHLBI Policy  ...............................  107 
Appendix 9: Flow  Diagram  for Expedited Reporting of  Serious  Adverse  Events  and  
          Serious  Unanticipated Problems ................................ ................................ .... 108 
Appendix 10: Research Coordinator -AE/UP Form  ................................ ..............................  109 
Appendix 11: Clinical Pharmacist  AE/UP  Form  ................................ ................................ . 110 
Appendix 12: Physician Monitor SAE/UP Report Form  ................................ .....................  111 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version 2.0  Page 4 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  ABBREVIATIONS  
 
ACE â€“ Angiotensin -converting enzyme  
ARB â€“ Angiotensin II Receptor Blocker  
BP â€“ Blood Pressure  
CAPI â€“ Computer Assisted Personal Interviewing  
CCB â€“ Calcium -channel blocker  
CLIA  â€“ Clinical Laboratory Improvement Amendments  
CRF â€“ Case Report Form  
CS â€“ Cedars -Sinai  
CTSI â€“ Clinical and Translational Science Institute  
DCC â€“ Data Coordinating Center  
DSMB â€“ Data Safety Monitoring Committee  
GFR â€“ Glomerular Filtration Rate  
Hg â€“ Mercury  
HIPAA â€“ Health Insurance Portability and Accountability Act  
HTN â€“ Hypertension  
IRB â€“ Institutional Review Board  
LA â€“ Los Angeles  
MD â€“ Doctor of Medicine  
mm â€“ millimeters  
NCATS â€“ National Center for Advancing Translational Science  
NH â€“ Non-Hispanic  
NHLBI â€“ National Heart, Lung, and Blood Institute  
NIH â€“ National Institutes of Health  
PHI â€“ Protected Health Information  
PI â€“ Principal Investigator  
[INVESTIGATOR_88070]/UPs â€“ Serious A dverse  Events  and serious Unanticipated Problems  
UCLA â€“ University of [LOCATION_004], Los Angele s 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol Version 2.0  Page 6 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  STUDY SUMMARY  
Title IMPLEMENTING THE LOS ANGELES BARBER -PHARMACIST MODEL 
OF HYPERTENSION MANAGEMENT IN NASHVILLE  
Short Title  Barbershop Nashville  
NIH Grant Number  UL1TR001881 -03S2  
Protocol Number  NSH -BP001  
Clinicaltrials.gov 
Registration  [STUDY_ID_REMOVED]  
Phase  2A 
Design  Open label, single arm  pre-test/post -test design, with no compar ator 
Study Duration  6-Months
Clinical Site(s)  Vanderbilt University Medical Center; Community partners  (Barbershops)  
Data Coordinating 
Center  Cedars -Sinai Health System  & University of [LOCATION_004] Los Angeles (UCLA)  
Program contact:  , PhD  (UCLA)  
Primary Objectives  Establish network of Nashville barbershops engaged in clinical research ; 
localized version of the LA -BP program  
Secondary 
Objectives  Evaluate the impact of a pi[INVESTIGATOR_202875]  56 clients  
Inclusion criteria  Adults 35 -79 years old, non-Hispanic  black males, patron of one of the 
participating barbershops ( > [ADDRESS_242090] 6 months), Systolic BP > 
[ADDRESS_242091] counseling & medication management ; Barber 
encouragement & BP measurement  
Primary outcome s a. Recruitment/retention of participants
b. Intervention Fidelity
c. Clinical efficacy: BP at 6 -months; participant satisfaction
Statistical 
methodology  Primary analyses will estimate the average change in systolic blood 
pressure  from baseline to 6 months and derive its 95% confidence interval . 
Secondary analyses will measure  associations between relevant baseline 
covariates and BP at [ADDRESS_242092] a participantâ€™s response. Longitudinal analyses using 
mixed effects models of serial systolic BP measurements obtained at each 
individual visit from baseline to 6 months will also be conducted . 
Study oversight  Data Safe ty Monitoring Committee  
Reviewed and approved by: 
[INVESTIGATOR_202874], MD, Principal Investigator  [CONTACT_1782]:  
Barry Carter, PharmD, Chair, Data Safety Monitoring Committee  Date:  

 
Protocol Version 2.0  Page 7 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
INTRODUCTION  
1. Background  
Black men face a shorter life expectancy than white men because of higher prevalence and worse 
outcome from many diseases: most notably hypertension (HTN) and its cardiovascular 
complications but also chronic kidney disease, tobacco -related diseases, prostate and lung 
cancer, depressio n, and HIV/AIDS.[ADDRESS_242093] research is based. Black 
barbershops are uniquely positioned in the community for promoting health and health research 
among male patrons in a relaxed social setting.  
 
Engaging underrepresented  groups in clinical research is both a challenge and a p ublic health 
priority for reducing health disparities.2 Engaging non -Hispanic black individuals â€”particularly 
black men â€”in research has been especially challenging.  For example, the age -adjusted death 
rate from prostate cancer is 3 -times higher for black me n than white men  but black men comprise 
<4% of patients in National Cancer Institute prostate cancer trials.3 The HTN -related  death rate 
also is 3 times higher in black men than white men.4 However, in the Dallas Heart Study, which  
addressed this disparity , the in -home phlebotomy participation rate was 64% among black men 
vs. 72% among  black women and 82% and 86% among white men and women, respectively.[ADDRESS_242094] not been very productive. In Dallas County  
Community Oriented Primary Care Clinics, <20% of black clinic patients with HTN are men. In a 
recent trial that  recruited black patients from community pharmacies in Wisc onsin for an 
intervention trial to improve medication  refill rates, only 1/3 of the ~ 600 black patients enrolled 
were men.6 Together, all these data underscore the need to reach out to non -traditional 
community partners and develop health messages that re sonate with black men.  
 
Black barbershops are a unique social  setting  in which  black men to openly discuss important 
issues in their lives â€”including health â€”with barbers (trusted  community members with a loyal 
clientele) and other black men. Barbershop hea lth outreach is well -established but previously 
untested as a vehicle to engage black men as participants in research. A series of successful 
intervention trials in other cities serve as a model to evaluate the implementation of a pi[INVESTIGATOR_202876].  A key issue is distrust of doctors and fear exploitation by [CONTACT_33365] â€”a reaction to 
unequal medical treatment9 and prior scientific misconduct as in the Tuskegee Syphilis Study.10 
In the 1920s, indigent black men in Alabama were recruited by [CONTACT_941] U.S. Pu blic Health Service for 
this natural history study before penicillin was discovered as effective treatment for syphilis; 
however, participants were not informed of the studyâ€™s true purpose and they were not offered 
appropriate antibiotic treatment for [ADDRESS_242095]. BP measurement is non -invasive. The BP 
cuff is a familiar iconic symbol of healthcare and community screening programs. HTN is 
 
Protocol Version 2.0  Page 8 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  particularly devastating for black men and is the main reason why average life expectancy is still 
less than for white men.11 High BP medication reduces the risk of heart attack, stroke, heart failure, 
and premature death for all patient groups, including black men.12 HTN exemplifies the barriers 
to effective chronic disease management in general. High BP signifies multiple related health 
issues (such as dyslipi[INVESTIGATOR_035], metabolic syndrome, diabetes, tobacco addiction) that also will 
come to medical attention.  
 
Prior  research trials in Dallas, [LOCATION_007]  and then Los Angeles, [LOCATION_004] , supported by [CONTACT_202928],  
showed that barbershops can support health services research and provide effective  HTN 
screening, referral, and follow up centers for black men. The  Los Angeles  study developed a 
network of [ADDRESS_242096] team approach to manage chronic diseases (starting 
with HTN) in barbershops. The barbershops enrolled 320 hypertensive black male patrons to 
participate in a 12 -month HTN trial with 97% cohort retention. A lso, the screening process 
generated a local registry of >2,[ADDRESS_242097] case for: A) recruiting regular patrons with uncontrolled HTN, B) conducting a 
research protocol and evaluating a HTN intervention; and C) creating a local registry of potential 
subjects as platform for enrolling black men in future research studies.  
 
There is no formal hypothesis testing regarding patient -level outcomes, however this study will 
evaluate : 
 
a) the ability of the barbershop -based research methodology to recruit and retain black men 
in a clinical trial;    
 
b) intervention fidelity by [CONTACT_202929], pharmacist, and hypertensive male participants;  and  
 
c) intervention effectiveness on the primary outcome of systolic BP and patient satisfaction.  
 
All screening participants will also be offered opportunity to participate in a separate research 
registry  (Patientsâ€™ Research Networking and Engagement Registry for Cardiovascular and Kidney 
Disease: PARTNER CKD; VUM C IRB# 191374) .  
 
3. Study Design and Overview  
Single arm, pre -test/post -test (Phase 2A) design, with no comparator group.  
 
4. Participant Selection and Withdrawal  
4.1 Barbers & Barbershops  
North Nashville has approximately 1.6 black barbershops per square mile, with only 3.4 miles 
being the maximum distance between shops. Thus, North  Nashville is well -suited to develop 
barbershops as hubs for much needed HTN health services research. Barbershops in this area 
will be prioriti zed, however other areas will be considered as needed to meet participation goals.  
 
 
Protocol Version 2.0  Page 9 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  A lead study  barber  or investigator  will identify and recruit [ADDRESS_242098], the activities and expectations and answer any questions or concerns. 
If the barber shop owner  agrees to parti cipate  as a location , they will sign a Letter of Collaboration 
(Appendix 6A). The target will be 8 barbershops . 
  
Barbershops will meet these general selection criteria: a) NH black owner; b) estimated >95% 
black male clientele  as reported by [CONTACT_136253] ; c) 1 0+ years in business; d) barbersâ€™ commitment 
to the study; and e) large enough clientele to enroll >7 patrons with high BP.  
 
Once a barbershop has agreed to participate, each barber working within that shop will be 
approached  for participation in the study as a barber (secondary participant).  The only inclusion 
criteria are that the barber is fluent in English and willing to commit to training.  They will be 
approached in person to discuss the activities of participation. All b arber questions will be 
answered. If the barber agrees to participate,  he will sign the VUMC  IRB approved  barber  consent 
form. The barber will agree to participate in study training. If they do not complete study training,  
they will not participate. Barbers may withdraw from participation at any time by [CONTACT_202930].  
 
4.2 Participant Inclusion & Exclusion Criteria  for participants  
Inclusion criteria:  
a. Adults 35-79 years  old 
b. Self-identi fy as Non-Hispanic black male   
c. Patron of one of the participating barbershops  (> [ADDRESS_242099] 6 months)  
d. Systolic BP > [ADDRESS_242100] one day apart  
 
Exclusion criteria:  
a. Severe cognitive impairment   
b. Non-fluent in English  
c. Women  
d. Age < 35 years  or > 79 years  
e. Systolic BP < 140 mm  Hg at either screening  
f. Current ly receiving  chemotherapy  for cancer  
g. Organ transplant patient  
h. Currently receiving  dialysis  
i. Other conditions the physician investigators deem unsafe to participate  
j. Plans to move/relocate in next 12 -months and/or travel out -of-area for > 1 month   
 
4.2.1 Pre -screening and enrollment of participants  
Trained study personnel  will screen the black male clientele of the study  barbershops to identify 
and enroll r egular patrons 35 -79 years of age with systolic BP >[ADDRESS_242101] 
been met for each barbershop . Those with systolic BP >140 mm  Hg will be asked to return within 
3 week s to: (a) complete a 2nd set of BPs, (b) complete the visit screening questionnaires (see 
Appendi ces 6B.1-6B.2), and (c) bring their pi[INVESTIGATOR_202877] 2  so that medication data 
can be transcribed.  
 
Protocol Version 2.0  Page 10 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
Eligible participants at screening visit 2 will be offered the opportunity to participate in the study. 
An informed discussion will occur with the study personnel during which  all questions may be 
answered. If the participant agrees, written informed consent will be obtained emphasizing this is 
a voluntary study and participation may be withdrawn at any time.  
 
The participantâ€™s existing physician  (VUMC)  or Dr.  (or other study physician) , must sign 
the collaborative practice agreement (see Appendix 3) for the pharmacist to provide care and also 
to prescribe medications within this study protocol. All participants in this study will execute a visit 
with the study MD for an evaluation to est ablish care, supported by [CONTACT_202931] 
(e.g. NIH).  If the participant is seen by a VUMC physician, and that physician would prefer to 
serve as the supervising physician  of the pharmacist including all regulatory oversight this will be 
permitted.  These visits  will be performed after enrollment, but prior to any hypertension 
management.  
 
Interviewers will invite patrons who screen -fail to join a new separately VUMC IRB approved 
registry  (IRB# 191374)  by [CONTACT_202932] -contact[CONTACT_202933]. Those completing the [ADDRESS_242102]  or an 
investigator .  
 
Barbers will frequently check and transmit the BP readings  (See Section 5.4)  of their enrolled 
patrons  and motivate them to work with the clinical pharmacist, who will meet them in their 
barbershops  or other mutually agreed location  to optimize BP medication.  
 
5.[ADDRESS_242103] evaluation and counseling  
With the VUMC or study  physici ansâ€™ permission and oversight, the pharmacist will promote patient 
activation, intensify drug therapy under a collaborative practice agreement as permitted by 
[CONTACT_202934], send progress notes to the  participantsâ€™  physicians  with their permission , 
and ensure appropriate safety monitoring after each medication change. The study clinical 
pharmacist will follow the trialâ€™s medication algorithm, which is consistent and not different than 
standard of care . The pharmacist will  preferably be certified as a Clinical  Hypertension Specialist  
from the American Society of Hypertension .  
 
The pharmacist will meet each participant in his barbershop  or other mutually agreed location  
every week at first and then less often  (monthly)  once the target BP goal has been achieved . The  
pharmacist will send progress notes to the participantsâ€™ physicians after each encounter.  
Pharmacist will share treatment/BP reports with enrolled participants during their visits. These 
reports are generated by [CONTACT_202935] (UCLA) and shared with the study team. 
(Appendix 6 G). The pharmacist will work with the research assistant to schedule participant 

 
Protocol Version 2.0  Page 11 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  appointments with the pharmacist, make reminder calls, and obtain  or share  medical records from 
the participantsâ€™  physicians.  
 
5.[ADDRESS_242104] and  study team  
will interview the  participants and those who achieve BP control will be invited to become a study  
role model .  
 
If they agree , the research  assistant will take  a photograph of the role model, and (with the modelâ€™s 
approval) ha ve the poster gen erated at a copy shop and place it on the wall of the barbershop. 
Each poster models one of two desired behaviors (have the barber check the BP after every 
haircut or meet the pharmacist in the barbershop), and, in the modelâ€™s own words, briefly states 
one common barrier to the behavior change, one facilitating factor, and one positive outcome.  
 
5.4 Blood Pressure measurement and data transmission  
UCLA -CS will supply Nashville with Barbershop BP Carts. T hese nursesâ€™ carts are modified with 
a highly -rated a utomated BP monitor that is programmed to take 5 readings, which upload 
immediately to a desktop computer that automatically transmits the readings by [CONTACT_202936], MD; the n de-identified  data are transmitted every even ing to the 
UCLA -CS CTSI  under the supervision of Dr. , or approved personnel at UCLA . Westat, 
Inc. is the data management company that collaborated with the LA Barbershop study and will 
offer ongoing support to this study, leveraging its already de veloped methodology.  
 
5.[ADDRESS_242105] or study physician will 
generate relev ant orders as needed & complete medical record documentation  
 
5.6 Monitoring the fidelity of the Intervention  
Treatment fidelity involves three components: 1) treatment delivery , 2) receipt , and 3) enactment . 
Treatment delivery  by [CONTACT_202937]  (BP checks)  will be assessed by [CONTACT_202938]. After observing a mock barber -patron in teraction, 
the assistant will complete detailed checklists to evaluate performance of the desired 
competencies and intervention delivery, followed by [CONTACT_202939].  
 
Treatment delivery by [CONTACT_202940] (Dr.  or other 
study designated physician ), who will review  with the pharmacists each week t heir progress notes 
to ensure adherence  to the study algorithm as well as perform quality performance review . 
Treatment receipt  will be assessed a) by [CONTACT_202941] d uring each in -person visit by [CONTACT_202942]; and b) by [CONTACT_202943] a [ADDRESS_242106] encounters, and model posters.  
 
6. Ascertainment of Outcomes  
6.1 Recruitment and retention of black men  
All people screened at each of the screening days will be tabulated and descriptive statistics 
performed. For those that enroll, their activities throughout the 6 -month study timeline will be 

 
Protocol Version 2.0  Page 13 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  7. Study Procedures and Visits  
7.[ADDRESS_242107] month of the study, all adult black men entering the study barbershop will be offered 
free BP screenings. This will be in person. Men with systolic BP >[ADDRESS_242108].  The research team member will call the potential participant to remind them of SV2 
appointment no more than 3 times in the eligibility i nterval.  All men completing this initial screening 
visit will receive a water bottle or other similar gift as a token of appreciation . The script and 
content of the screening visit are described in Appendix 6B.1  (Screening Visit 1 Survey). All data 
collect ed in this screening visit will be directly entered into the on -site study computer to a secure 
web portal specific to this study. This is managed by [CONTACT_202944], Inc.  
 
In addition, all men completing the first screening visit (regardless of  their eligibility to join the HTN 
pi[INVESTIGATOR_4251] ), will be invited to join a registry by [CONTACT_202945] -contact[CONTACT_202946]. 
This is a separate IR B approved study with its own procedures and documents  (Patientsâ€™ 
Research Networking and Engagement Registry for Cardiovascular and Kidney Disease; 
PARTNER CKD; VUMC IRB# 191374).  
 
7.1.2 Second screening day  
Those invited to participate in the second scre ening visit will be asked to: (1) complete a 2nd set 
of BP measurements and health questionnaire  (Appendix 6B.2; Screening Visit 2 ) and (2) bring 
their pi[INVESTIGATOR_202878]. Subjects with 
systolic BP >140 mmHg on both days who meet all other inclusion criteria will be enrolled after 
informed written consent has been obtained by [CONTACT_102867] . 
 
7.1.3 Enrollment & Initial activities  
Informed consent will be obtained,  and the participant will provide written documentation.   
 
Visit questionnaires  for baseline  (Appendix 6B.2 ), 3-month telephone visit,  and 6 -month endpoint 
assessment visits will be completed by [CONTACT_202947] , or by [CONTACT_37261] . The data will include detailed demographic and 
identification information: marital status, phone number, add ress, and email address. Structured 
response items  will includ e barbershop patronage, hypertension/medication history, comorbid 
conditions/family history, medication adherence, quality of life, health care access and utilization, 
and satisfaction with medical care.  Five BP measurements will be taken and recorded at ba seline 
using the same cuff size as recorded at screening.  
 
7.1.[ADDRESS_242109] of medication -related problems, which 
is included in the Progress Note, at each encounter (see Appendix 6D & 6E ). A checklist of 
actions/interventions will also be completed. If an adverse event is reported, the pharmacist will 
 
Protocol Version 2.0  Page 14 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  complete an Adverse Event form. Pharmacist and/or physician will also record all necessary 
information in the VUMC electronic medical record.  
 
The research team will attempt to contact [CONTACT_202948] a haircut in [ADDRESS_242110] visits as well as 3-
month telephone and 6-month data collection.  
 
7.1.5 Study close visit (6 -months)  
The research assistant will perform a blood pressure assessment and questionnaires as in 
Appendix 6B.4.  
 
Data will be collected on performance and acceptability of the study protocol using open ended 
interview questions.  
 
7.1.6  Barber survey  
All participating barbers will be asked to complete a brief survey about their experiences in the 
study (Appendi x 6B.5). This data will be collected in R EDCap and by [CONTACT_202949].  
 
7.2 Client  compensation  
Participants will be offered $25 at the completion of the second  screening visit regardless of 
eligibility . Participants will be offered $[ADDRESS_242111] (up to 6 visits ; the participant may have additional visits if needed without 
additional compensation ), $15 for the telephone interview  and $100  at the completion of the final 
6-month visit.  Participants will also be offered a monthly $25 haircut voucher  in addition to the 
above . The total potential compensation if all study activities are completed is $440  (direct 
payment and haircut vouchers) . Participants may be asked to complete a W -[ADDRESS_242112] program and / or pre -
paid gift cards , or check .  
 
7.3 Barber and barbershop compensation  
Each barbershop will receive a flat fee of $1000.00 ($500.00 at the beginning of the study and 
$500.00 after study completion). Each barber will receive $10.[ADDRESS_242113]  approx imately  
7 participants, this would equate to $840.00 per shop (14 x 6 months = 84 BP measurements = 
$840.00 per shop). Barbers will also redeem submitted study hair cut vouchers ($25.00/each). 
Barbers and barbershops may be asked to complete a W9 form to r eceive payment. Payment will 
be by [CONTACT_9434], or prepaid gift card for activity over the prior month.  
 
8. Statistical Analysis Plan  
Primary analysis  (clinical outcomes) :  
Since this study has no comparison group, our initial analysis will focus on estimating the average 
change in systolic BP from baseline to 6 months and derive its 95% confidence interval, that is, 
our goal is to estimate ğ‘‘ = ğ¸[ğ‘†ğµğ‘ƒ 6ğ‘š â€“ ğ‘†ğµğ‘ƒ 0], where  E stands for expectation, and ğ‘†ğµğ‘ƒ 0 and 
ğ‘†ğµğ‘ƒ 6ğ‘š denote baseline and 6 months systolic BP, respectively. Let ğ‘‘ğ‘–ğ‘— be the systolic BP change 
score from baseline to 6 months on individual j in barbershop i. Define  
 
Protocol Version 2.0  Page 15 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  ğ‘‘Ì…ğ‘–=âˆ‘ ğ‘‘ğ‘–ğ‘—ğ‘šğ‘–
ğ‘—=1
ğ‘šğ‘– 
the observed m ean change of systolic BP in barbershop i, where ğ‘šğ‘– is the sample size for 
barbershop i. An estimate of ğ‘‘ can be derived using weighted average of ğ‘‘Ì…ğ‘– over all the 
ğ‘› barbershops ( ğ‘› = 8 in this study). The optimal weights are given by [CONTACT_202950] o f the variance 
of each cluster summary :22 
ğ‘¤ğ‘–=ğ‘šğ‘–
1+ ğœŒ(ğ‘šğ‘–âˆ’1), 
 where ğœŒ is the intracluster correlation coefficient (ICC). Thus, we estimate ğ‘‘ by ğ‘‘Ì…: 
ğ‘‘Ì…=âˆ‘ ğ‘¤ğ‘–ğ‘‘Ì…ğ‘–ğ‘›
ğ‘–=1
âˆ‘ ğ‘¤ğ‘–ğ‘›
ğ‘–=1. 
The 95% confidence interval is given by ğ‘‘Ì… Â±ğ‘¡ğ‘£,0.025 ğ‘ ğ‘¤/âˆšâˆ‘ ğ‘¤ğ‘–ğ‘›
ğ‘–=1, where the degrees of freedom 
ğ‘£ for the t -distribution is âˆ‘ ğ‘¤ğ‘–ğ‘›
ğ‘–=1 âˆ’1 and ğ‘ ğ‘¤ is the square root of the empi[INVESTIGATOR_202879]  
ğ‘ ğ‘¤2=âˆ‘ ğ‘¤ğ‘–(ğ‘‘Ì…ğ‘–âˆ’ğ‘‘Ì…)2 ğ‘›
ğ‘–=1
ğ‘›âˆ’1. 
Secondary Analyses:  
Three sets of secondary analyses will be conducted.  First, we will examine the impact of baseline 
covariates on the outcome. We will focus on the same covariates used in the LA Barbershop 
study: baseline systolic BP, high cholesterol (yes/no), and whether there is a doctor for routine 
medical care (yes/no) . Graphs for blood pressure trajectories and latent class growth analysis will 
be used to classify the participants into those who respond well to the intervention and those who 
do not respond well. Important covariates that predict participantâ€™s response will be identified via 
logistic regression. Second, we will conduct longitudinal analysis of serial systolic BP obtained on 
each individual from baseline to [ADDRESS_242114] 
for the c ovariates identified above. We will examine the trend (trajectory) by [CONTACT_202951]. This will be done for each barbershop separately. Third, we will compare 
data from this study with the intervention arm of the LA Barbershop stu dy to see if there is a 
systematic difference. The comparison will be done for the change score of systolic BP at [ADDRESS_242115] missing BP data due to dropout and/or intermittent missing data at the individual level 
but not at the shop level, where dropout is ex pected at baseline when accrual targets are unmet; 
after baseline, missing data will be from individuals not shops. The following analyses will be 
 
Protocol Version 2.0  Page 16 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  conducted if the rate of missing data exceeds 10% at [ADDRESS_242116] 
missing data mechani sm beforehand, we will compare results of two sets of  analyses: (1) The 1st 
set is based on multiple imputations, i.e., missing BP data â€œfilled inâ€ by [CONTACT_202952]. Five 
imputed datasets are generated by [CONTACT_202953].24 Analysis wi ll be 
conducted within each imputed dataset using linear mixed effects models. Results of imputed 
datasets will be combined to produce final estimates. This approach assumes data are missing 
at random (MAR): the mechanism that gives rise to missing data re lies on observed data only. 
However, missing data from cohort attrition and intermittent missing data due to low treatment 
efficacy may be missing not at random (MNAR); the probability of missing data may be related to 
unobserved (and possibly high) BP. He re the multiple imputation method will produce biased 
efficacy estimates. (2) The 2nd approach relies on joint modeling of longitudinal BP data and 
missing data mechanisms for dropout and intermittent missing data MNAR.[ADDRESS_242117]/post -test design; thus, the identification of missing data 
models is not as  powerful as it would be in a longitudinal design.  
9. Adverse Events  
9.1 Potential Adverse Events from study interventions  
The likelihood of adverse events beyond those that may be expected as a result of hypertension 
medication management are minimal.  
 
Loss of confidentiality is a serious risk in any clinical research; however, is not likely given the 
safeguards we have esta blished to protect and maintain the research data collection, 
transmission, and storage.  
 
Anxiety is a rare and typi[INVESTIGATOR_202880]â€™s BP is elevated. Study personnel will undergo training  in all study procedures which will 
include appropriate interaction with subjects.  
 
Uncontrolled hypertension is associated with increased risks of known hypertensive 
complications including cardiovascular  events, stroke, heart failure, and chronic kidney disease. 
These risks are not due to study procedures but are intrinsic to the condit ion of all subjects being 
enrolled. The purpose of our  study is to reduce these risks by [CONTACT_202954].   
 
During the data collection periods (baseline, 6 -month follow -up), all subjects will receive a form 
with their BP reading, an explanation of  the accepted cutoff values for normal and high BP, and 
suggestion for medical follow -up based on the degree of elevation as below:  (Appendix 6 C) 
â–ª For normal BP range of below 120/[ADDRESS_242118] once a year to maintain good health.  
â–ª For high normal range BP of 120/80  mm Hg -139/89  mm Hg , subjects are advised to see 
a doctor within 6 months.  
â–ª For elevated BP range of 140/90  mm Hg -159/99  mm Hg , subjects are advised to see a 
doctor within the next 1 month.  
 
Protocol Version 2.0  Page 17 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  â–ª For very elevated BP range of 160/100  mm Hg -179/109  mm Hg , subjects are advised to 
see a doctor within the next 2 weeks . 
â–ª For extremely elevated BP range of 180/110  mm Hg -199/119  mm Hg , subjects are 
advised to see a doctor in the next 3 days.  
â–ª For alarmingly elevat ed BP of 200/[ADDRESS_242119] for personalized health 
management and to their barber for frequent BP monitoring and social support. The risks of 
uncontrolled HTN are not due to study procedures but are intrinsic to the condition of all subjects 
being enrolled.  
 
Adverse drug reactions :  
Although not common, there are potential serious adve rse drug reactions associated with BP 
medication, but the most common side -effects from blood pressure medication are not serious 
and resolve within three days after the medication has been stopped. In addition, excessive fall 
in blood pressure is a potent ial serious risk of any blood pressure medication.  
 
9.2 Monitoring for Adverse Events  
Adverse Events procedures and forms are included in the Appendix (Appendi ces 8-12). These 
forms include  description of the event, event onset and end date, disease -related complications, 
checklist of drug or non -drug related events, severity scale, whether or not the event was related 
to study procedures, event pattern, actions taken with study drug, whethe r or not hospi[INVESTIGATOR_65586]/or medication(s) were required.  
 
To track potential adverse events from added medications, pharmacist will 1) provide details 
about potential adverse reactions to each drug prescribed, 2) instruct subjects to call the 
pharmacis t immediately if they suspect an adverse drug reaction, 3) reduce or stop medication if 
systolic BP falls below 110 mmHg or diastolic BP falls below 60 mmHg as recommended by [CONTACT_202955], 4) make an additional follow -up phone call one w eek after medication 
changes, 5) go through a complete check list of potential adverse events at each encounter (in 
person visit and via telephone) to assess the presence and severity of all reported reactions, 6) 
send a detailed Progress Note (Appendix 6D  & 6F ) to the subjectsâ€™ physicians after every in -
person and telephone encounter with the subjects. The Progress Note used for the in -person and 
telephone encounters will have a complete check list of potential adverse drug reactions to every 
class of bloo d pressure medication included in the signed treatment protocol. The adverse drug 
reaction check list includes  the following items:  
â–ª Calcium channel blocker: lower extremity edema, bradycardia, hypotension, gingival 
hyperplasia  
â–ª Angiotensin converting enzyme  inhibitor/angiotensin receptor: cough, hyperkalemia, 
acute renal failure, alopecia, angioedema  
â–ª Thiazide/thiazide -like diuretic: erectile dysfunction, hyperglycemia, hyperuricemia, gout, 
hypokalemia, hyponatremia  
â–ª Vasodilating beta -blocker: wheezing, erectile dysfunction, depression, heart block  
â–ª Aldosterone antagonist: gynecomastia, hyperkalemia, acute renal failure, erectile 
dysfunction  
â–ª Alpha blocker: dizziness, orthostatic hypotension, lower extremity edema, heart failure  
â–ª Centrally acting s ympatholytic: rebound hypertension, dry mouth, somnolence  
â–ª Direct Vasodilator: headache, palpi[INVESTIGATOR_814], shortness of breath, lupus (hydralazine), 
pericarditis (hydralazine)  
â–ª Loop diuretic: acute renal failure, hypokalemia  
 
Protocol Version 2.0  Page 18 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
In addition, the study physicians  will meet regularly with the pharmacist to review Progress Note 
and ensure protocol adherence. Subjects will receive detailed instructions from the pharmacist 
about potential adverse reactions to each drug prescribed and to call the pharmacist immediately 
if they suspect an adverse drug reaction.  This will occur locally at VUMC. In addition, the study 
physician at Cedars Sinai will review de -identified progress notes for adherence to the study 
hypertension algorithm and to offer any further oversight recommen dations.  
 
9.[ADDRESS_242120] emergency room for any 
symptoms suggestive of heart attack, stroke, other serious medical condition, or extremely rare 
serious adverse events from BP medication (e.g., severe angioed ema from an ACE inhibitor).  
 
10. Data Management  
10.1 Data coordinating Center and Data Entry Overview  
The coordinators/study personnel  and the pharmacist will collect and transmit data electronically 
via a secure internet connection to the existing Westat  server, which transmits the data to the 
UCLA CTSI Data Coordinating Center.  
 
Data collected by [CONTACT_202956] a VUMC REDCap Study database. This deidentified dataset will be shared with the 
coordinating center (UCLA) and other approved study investigators . Pharmacist Progress Note; 
copi[INVESTIGATOR_202881]/Termination forms ; copi[INVESTIGATOR_202882] ; copi[INVESTIGATOR_202883] /HIPAA waivers; authorization for 
release of medical records; medical records sent by [CONTACT_748]â€™ physicians; transmitted barber 
BP measurements; and signed collaborative practice agreements will be placed in the subjectâ€™ s 
research chart which will be stored in a locked cabinet only accessible by [CONTACT_202957] . Hard copi[INVESTIGATOR_73749] a secured 
locked cabinet at Vanderbilt  University Medical Center - Cente r for Health Services Research . 
Additionally , electronic files may be stored on password protected Center for Health Services 
Research serve rs that are only accessible to approved study personnel.  
 
The following individuals will have access to individually  identifiable private information about 
human subjects: VUMC study personnel as designated to the IRB  will have access to the data 
collected at screening, baseline, 3-month and 6-month assessment visits.  The data management 
team, Westat Inc, will have acce ss to identified information during screening and the study data 
collection.  The database manager at the UCLA DCC  will have access to the data collected by 
[CONTACT_202958] -identified . The pharmacist will have access to the data 
collected by [CONTACT_28932] , data provided by [CONTACT_423]â€™s own physician, the BP 
measurements transmitted by [CONTACT_202959], and the information obtained directly from the subject. 
The study subjectâ€™s own physician will have access to the data collected  by [CONTACT_202960].  
 
 
Protocol Version 2.0  Page 19 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  10.[ADDRESS_242121] private health information: 1) each potential subject is given a unique code name [CONTACT_203020], 2) CAPI [INVESTIGATOR_202884]; the data are continually uploaded to a 
secured server and the laptop is automatically erased - if the laptop is stolen, it contains no data; 
3) the survey data are encrypted and transferred via a secure web -based system to the data 
management software and hardware systems at Westatâ€™s Rockville, M aryland central offices. 
Periodically, the encrypted de-identified data are transferred to the DCC at UCLA,  4) once the 
UCLA data manager reviews the validity and completeness of data, the data is deleted from the 
Westat servers and maintained solely at UCLA; 5) the linking file to PHI is locked and stored at 
Vanderbilt . Except for the Westat system, all other data management elements have been used 
in many previous NIH trials. Westatâ€™s system has been used in many previous research projects.  
 
11. Study Oversight  
This trial will be monitored by [CONTACT_202961] (R01 HL 117983), and it will utilize a similar  DSMB plan.  The DSMB  is responsible  
for safeguarding  the interests  of study  participants  by [CONTACT_202962], and  by [CONTACT_202963].  The 
DSMB  reviews  the following  types  of safety  data: 1) quarterly  reports from the UCLA DCC; 2) 
annual reports  from DSMB  meetings;  and 3) expedited reports from the PI [INVESTIGATOR_202885]/UPs 
or concerning trends  identified  by [CONTACT_202964]. After reviewing  pertinent reports, the 
DSMB  determines  whether  any trend  that may be identified  is related  to the trial. After each  DSMB  
meeting,  the study team will prepare a draft report for the  DSMB  Chair  to review and sign .  The 
VUMC PI [INVESTIGATOR_202886]. The report summarizes  the recommendations  of the 
DSMB  regarding  the safety  and continuance  of the study and  should  be sent to the PI [INVESTIGATOR_874]  [ADDRESS_242122]  current  and potential  
participants. The DSMB is chaired by  (licensed pharmacist and board -
certified pharmacotherapy specialist) who is experienced with DSMBs. Other DSMB members 
are  (Emeritus Professor of Biostatistics, Cornell University, Ithaca, New 
York) and  (Profe ssor of Medicine/Cardiology, Tulane University School of 
Medicine, New Orleans, Louisiana).  
 
  

 
Protocol Version 2.0  Page 20 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  REFERENCES  
 
1. Barnett, E., et al., Men and heart disease: An atlas of racial and ethnic disparities in 
mortality.  2001.  
2. Prevention, U.S.D.o.H.a.H.S.C.f.D.C.a. A Closer Look at African American Men and High 
Blood Pressure Control . 2018; Available from: 
http://www.cdc.gov/bloodpressure/docs/ african american sourcebook.pdf . 
3. Randolph, T.C., et al., Associations Between Blood Pressure and Outcomes Among 
Blacks in the Jackson Heart Study.  J Am Heart Assoc, 2016. 5(12). 
 
4. Go, A.S., Heart Disease and Stroke Statistics -2013 Update: A Report Fro m the 
American Heart Association (vol 127, pg e6, 2013).  Circulation, 2013. 127(23): p. E841 -
E841.  
 
5. Jones, L. and K. Wells, Strategies for academic and clinician engagement in community -
participatory partnered research.  JAMA, 2007. 297(4): p. 407 -10. 
 
6. Merrill, R.M. and O.W. Brawley, Prostate cancer incidence and mortality rates among 
white and black men.  Epi[INVESTIGATOR_623], 1997. 8(2): p. 126 -31. 
7. Victor, R.G., et al., The Dallas Heart Study: A population -based probability sample for the 
multidisciplinary  study of ethnic differences in cardiovascular health.  American Journal of 
Cardiology, 2004. 93(12): p. 1473 -1480.  
8. Victor, R.G., et al., Factors associated with hypertension awareness, treatment, and 
control in Dallas County, [LOCATION_007].  Arch Intern Med, 200 8. 168(12): p. 1285 -93. 
9. Svarstad, B.L., et al., Improving refill adherence and hypertension control in black patients: 
Wisconsin TEAM trial.  J Am Pharm Assoc (2003), 2013. 53(5): p. 520 -9. 
10. White, R.M., Unraveling the Tuskegee Study of Untreated Syph ilis. Arch Intern Med, 2000. 
160(5): p. 585 -98. 
11. Wang, J.G., et al., Systolic and diastolic blood pressure lowering as determinants of 
cardiovascular outcome.  Hypertension, 2005. 45(5): p. 907 -13. 
12. Victor, R.G., et al., A Cluster -Randomized Trial of Blood -Pressure Reduction in Black 
Barbershops.  New England Journal of Medicine, 2018. 378(14): p. 1291 -1301.  
13. Franklin, S.S., Cardiovascular risks related to increased diastolic, systolic and pulse 
pressure - An epi[INVESTIGATOR_202887] t's point of view.  Pathologie Biologie, 1999. 47(6): p. 594 -603. 
14. Franklin, S.S., et al., Single versus combined blood pressure components and risk for 
cardiovascular disease: the Framingham Heart Study.  Circulation, 2009. 119(2): p. 243 -
50. 
 
15. Parati , G., et al., European Society of Hypertension practice guidelines for home blood 
pressure monitoring.  J Hum Hypertens, 2010. 24(12): p. 779 -85. 
 
16. Whyte, J.L., et al., The challenge of controlling systolic blood pressure: data from the 
National Health a nd Nutrition Examination Survey (NHANES III), 1988 --1994.  J Clin 
Hypertens (Greenwich), 2001. 3(4): p. 211 -6. 
 
Protocol Version 2.0  Page 21 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
17. Anwar, Y.A., et al., Evaluation of the Datascope Accutorr Plus according to the 
recommendations of the Association for the Advancement of Med ical Instrumentation.  
Blood Press Monit, 1997. 2(2): p. 105 -110. 
 
18. Kronish, I.M., et al., Meta -analysis: impact of drug class on adherence to 
antihypertensives.  Circulation, 2011. 123(15): p. 1611 -21. 
 
19. Glasgow, R.E., et al., Development and validati on of the Patient Assessment of Chronic 
Illness Care (PACIC).  Med Care, 2005. 43(5): p. 436 -44. 
20. Kripalani, S., et al., Development and evaluation of the Adherence to Refills and 
Medications Scale (ARMS) among low -literacy patients with chronic disease.  Value 
Health, 2009. 12(1): p. [ADDRESS_242123] reliability of surveillance questions on health related quality 
of life.  J Epi[INVESTIGATOR_47779], 2003. 57(5): p. 339 -43. 
22. Hayes, R.J. and L.H. Moulton, Cluster rando mised trials . 2017: Chapman and Hall/CRC.  
 
23. Wong, M.D., et al., The contribution of specific causes of death to sex differences in 
mortality.  Public Health Reports, 2006. 121(6): p. 746 -754. 
 
24. Elashoff, R. and N. Li, Joint modeling of longitudinal an d time -to-event data . 2016: CRC 
Press.  
 
25. Schafer, J.L., Analysis of incomplete multivariate data . 1997: Chapman and Hall/CRC.  
  
 
Protocol Version 2.0  Page 22 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  APPENDIX 1: PARTICIPATING VUMC RESEARCHERS IN ADDITION TO PRINCIPAL 
INVESTIGATOR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  

 
[CONTACT_162797] 2.0  Page 24 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   APPEND IX 3: CLINICAL PHARMACIST COLLABORATIVE PRACTICE AGREEMENT  
Collaborative Pharmacy Practice Agreement  
â€œImplementing the Los Angeles Barber -Pharmacist Model of Hypertension  
Management in Nashvilleâ€  Study  
Medical Director:  
Definitions  
Collaborative Pharmacy Practice Agreement (â€œAgreementâ€) : A formal, voluntary and mutual 
agreement between the pharmacist and healthcare providers listed herein to  provide collaborative 
patient care services, optimize medication use, and achieve desired patient outcomes to patients 
under the care of Prescribers, and whose patients  are participants in the study titled 
â€œImplementing the Los Angeles Barber -Pharmacist Model of Hypertension Management in 
Nashvilleâ€ for the treatment of hypertension. This Agreement defines the scope of patient care 
services authorized to be provided by [CONTACT_32335], as well as the specific patient populations, 
prescription drugs, and di seases and conditions covered under this Agreement.  
Collaborating Professionals : Pharmacist and Prescribers, as defined below.  
 
 
  
 
   
Collaborative Pharmacy P ractice Agreement  
I. Collaborative Pharmacy Practice and Pharmacist Qualifications . Each Pharmacist 
named above is authorized to provide professio nal services within the scope of pharmacy 
practice as defined under Tennessee state law and within the collaborative pharmacy 
practice guidelines as described under this Agreement. Each Pharmacist (i) has been 
awarded a Doctor of Pharmacy degree from a program accredited by [CONTACT_202965], or has been awarded a Bachelor of Science in pharmacy 
and been in the continuous, active practice of pharmacy; and (ii) holds a current 
unrestricted license in good standing to practice pharmacy in the State of Tennessee.  
II. Pharmacist Scope of Services . The Pha rmacist is authorized to provid e the collaborative 
pharmacy services (â€œServicesâ€) as further described in Exhibit A, attached hereto and 
incorporated herein, as it relates to the care of Prescribersâ€™ patients who Prescribers have 
identified as subject to the collaborative treatment plan  in accordance with Section XII.  
 
 

 
Protocol Version 2.0  Page 25 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  III. Pharmacist Responsibilities.  
A. Provide all Services in accordance with this Agreement under the 
supervision of, or in direct consultation with the applicable Prescriber and 
maintain contact [CONTACT_202966] w ith each Prescriber;  
B. Provide Services only to patients for whom a current patient referral has 
been provided by [CONTACT_202967];  
C. Document all services in the medical record  on the same day the service is 
provided, including but not limited to patient/family education, patient 
assessments and plans and all medication orders;  
D. Utilize an area for in -person, telephonic or other approved consultations with 
patients that ensures t he confidentiality of the communication;  
E. When issuing a prescription order, as defined in T.C.A. Â§  63-10-204, or 
medical order, as defined in T.C.A. Â§63 -10-204, issue the prescription order 
or medical order in accordance with the requirements set forth in T.A.C. 
Â§ 1140 -03-.03 and within the terms set forth in this Agreement;  
F. Provide documentation of an initial prescription or a modification or 
discontinuation of a prescription to the Prescriber within [ADDRESS_242124] , unless more urgent notification is 
required under the circumstances and note the action taken in the patientâ€™s 
medical record ; 
G. Comply with all of the policies and procedures applicable to Vanderbilt 
University Medical Center (â€œVUMCâ€) pharmacy staff, all Tennessee  Board of 
Pharmacy rules and regulations, all guidelines, rules and standards of 
practice of the Tennessee Board of Medical Examiners, the Tennessee Board 
of Osteopathic Examiners, and all other Tennessee Health Related Boards, 
and all applicable laws and regulations governing the rendering of Services 
hereunder; and  
H. Complete at least ten (10) hours of the biennially required thirty (30) hours 
of continuing education in topi[INVESTIGATOR_202888], as mutually determined by [CONTACT_202968].  
IV. Prescriber Responsibilities.  
A. Retain ul timate authority and professional responsibility for his/ her patients 
for th e management of their drug therapy including routine review of 
pharmacy documentation in the electronic medical record . 
B. Establish and maintain a physician/provider -patient relationship with each 
patient receiving Services under this Agreement;  
C. Be available at all times through direct telecommunication for consultation, 
assistance and direction to the Pharmacist, or make arrangements for a 
substitut e physician to be available;  
 
Protocol Version 2.0  Page 26 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  D. Prepare a referral for each patient in accordance with Section XII and 
maintain the patient referral in the patientâ€™s medical record ; and  
E. Authorize only those Services within the routine scope of practice and 
services delivered  by [CONTACT_202969].  
V. Term and Termination.  
A. Term . This Agreement shall become effective on _____________, 201__ 
(â€œEffective Dateâ€) and shall remain in effect for two (2) years. This Agreement 
shall automatically extend for additional terms of one (1) year each; 
provided, however, that the Agreement must be reviewed and updated at 
least every two (2) years as evidenced by [CONTACT_202970], the Medical Director and the Pharmacy Director.  
B. Termination . This Agreement may be terminated at any time by [CONTACT_202971]. Any individual Collaborating 
Professional may terminate his or her participation in this Agreement upon 
thirty (30) days written notice to th e Medical Director and Pharmacy Director 
and all participating Collaborating Professionals. The Medical Director or the 
Pharmacy Director may terminate this Agreement immediately upon written 
notice to all other parties to the Agreement.  
C. Amendments . This A greement may be amended, including the addition of 
prescriber(s) and pharmacist(s), by [CONTACT_202972], the Medical Director and the Pharmacy Director.  
VI. Termination of Collaborating Professional.  A Collaborating Professional may be 
automatically excluded from participation in this Agreement upon the occurrence 
of any of the following, as determined by [CONTACT_202973]â€™s 
supervisor in accordance with VUMC policies and procedures:  
A. If Collaborating Professionalâ€™s license to practice medicine or pharmacy in 
Tennessee, as applicable, is suspended, revoke d, materially limited or not 
renewed.  
B. If Collaborating Professionalâ€™s right to prescribe is limited, suspended or 
revoked by [CONTACT_202974].  
C. If Collaborating Professional fails or refuses to abide by [CONTACT_202975].  
D. If Collaborating Professional engages in â€œWillful Misconductâ€. The term 
â€œWillful Misconductâ€ shall m ean only (i) arrest or indictment for, or 
conviction of, any crime; (ii) disruptive, unprofessional, inappropriate or 
unethical conduct as determined by [CONTACT_202976], in his or her sole discretion; (iii) fraud or theft relating  to the 
practice of medicine or pharmacy, or (iv) a determination made in good faith 
by [CONTACT_202977], safety, or welfare of patients is jeopardized.  
E. If the Collabora ting Professional is excluded from participation in any federal 
healthcare program.  
 
Protocol Version 2.0  Page 27 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  F. If the Collaborating Professional consistently fails to meet the quality and 
performance measures set forth in Exhibit B in accordance with Section IX.  
VII. Documentation and Co mmunication . All Services and communications related to each 
patient will be documented in VUMCâ€™s electronic health record, which is accessible by [CONTACT_202978].  
VIII. Method for Reporting Adverse Events to the Prescriber . All significant adver se effects 
or toxicities identified by [CONTACT_202979]â€™s research 
record  and communicated to the Prescriber in accordance with applicable VUMC policies 
and procedures. Significant events would include adverse events requiring therapy 
discontinuation planned for longer than [ADDRESS_242125] five 
percent (5%) of his or her patients treated pursuant to the Agreement. The quality 
assessments performed pursuant to this Section IX shall be documented and retained by 
[CONTACT_202980], and available for review by [CONTACT_202981] (10) years. All such quality assessments, reports, material and other 
documentation shall be created, used, annotated and maintained by a Quality 
Improvement Committee (QIC) pursuant to T.C.A. Â§Â§ [ADDRESS_242126]  via VUMCâ€™s electronic 
health record  and to the patient in accordance with applicable VUMC policies and 
procedures.  
XI. Biannual Review . The Pharmacy, Therapeutics and Diagnostics (PT&D) Committee shall 
review this Agreement at least once every tw o years.  
XII. Patient Referrals . Each Prescriber must complete a referral for each patient, as described 
in Exhibit C, which shall include, but not be limited to, a drug -specific, disease or condition -
specific plan of care for the patient. The referral will be maintained in the patientâ€™s medical 
record . VUMC pharmacy meets the definition of an Institutional -based pharmacy setting 
under T.C.A. Â§ 1140 -03-.17, and as such, is not required to obtain a general consent from 
patientâ€™s subject to Collaborative Pharmacy Practice Agreements  
XIII. Medical Records . Each Collaborating Professional shall maintain appropriate, accurate 
and complete medical records and business records in accordance with applicable law 
and VUMC record retention policies. The medical records  of the Services provided 
hereunder will be maintained for a period of at least ten (10) years.  
XIV. Accessibility . The Medical Director, Prescriber and Pharmacy Director shall maintain a 
copy of this Agreement, including any addendum, modification or termination at VUMC, 
 
Protocol Version 2.0  Page 28 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  which shall be accessible to each Collaborating Professional and made available to the 
applicable regulatory board for review upon request.  
XV. Compliance with Laws . Each party represents and warrants that he or she shall comply 
with al l applicable state and federal statutes, rules, regulations, including all laws and 
ethical principles concerning confidentiality of all individually identifiable health 
information, including, but not limited to, medical records . 
XVI. Written Attestation . The Medical Director and Pharmacy Director shall file a written 
attestation with the licensing boards for all Collaborating Professionals participating in this 
Agreement notifying those boards of the existence of this Agreement. The written 
attestation shall i nclude the names of all signatories and Collaborating Professionals 
participating in this Agreement, the effective date of this Agreement and a description of 
the scope of the services covered by [CONTACT_150419].  
[Signature [CONTACT_203021]]  
  
 
 
 
Protocol Version 2.0  Page 29 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Collaborative Pharmacy Practice Agreement  
â€œImplementing the Los Angeles Barber -Pharmacist Model of Hypertension  
Management in Nashvilleâ€ Study  
Signature [CONTACT_203022] a Collaborative Pharmacy 
Practice Agreement with individual healthcare pro viders in order to provide patient care services, 
optimize medication use, and achieve desired patientsâ€™ outcomes. By [CONTACT_17137], the 
named Physician(s) agree that the named Pharmacist may enter into a Collaborative Pharmacy 
Practice Agreement t o provide care for their patients.  
PRESCRIBERS:  
___________________  
 
_____________________________     _____________________  
[Insert Prescriber Name, Credentials, and Title]  Date  
 
_____________________________     _____________________  
[Insert Prescriber Name, Credentials, and Title]    Date  
 
_____________________________     _____________________  
[Insert Prescriber Name, Credentials, and Title]    Date  
 
_____________________________     _____________________  
[Insert Prescriber Name, Credentials, an d Title]    Date  
 
 
PHARMACIST:  
 
________________________________    _____________________  
[Insert Pharmacist Name, Credentials, and Title]    Date  
 
[Additional Signature [CONTACT_203023]]  
  
 
 
 
Protocol Version 2.0  Page 30 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
 
COLLABORATIVE PHARMACY PRACTICE AGREEMENT APPROVED BY:  
[CONTACT_202982]:  
________________________________     _____________________  
[Insert Medical Director Name, Credentials, and Title]   Date  
 
 
PHARMACY DIRECTOR:  
________________________________     _____________________  
[Insert Pharmacy Director Name, Credentials, and Title]   Date  
 
 
DATE APPROVED BY [CONTACT_6214]&D COMMITTEE:  ______________  
Expi[INVESTIGATOR_6054] 24 months from date of PT&D Committee VUMC Policy Reference: Collaborative 
Pharmacy Practice Agreements  
  
  
 
 
 
Protocol Version 2.0  Page 31 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Exhibit A  
Pharmacist Services  
A. Provide patient care and drug therapy management services to those patients who are 
being managed for hypertension . 
B. Provide drug therapy management services with respect to the medications commonly 
used to treat the above listed disorders. These medication s may include angiotensin -
converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, 
diuretics, beta -blockers, aldosterone blockers, central sympatholytics, alpha blockers, 
nitrates or other vasodilators. Order medication -relate d laboratory tests or obtain results 
from a fingerstick using a CLIA -waived point of care device. These laboratory tests may 
include blood chemistry/electrolyte panels or serum creatinine.  
C. Obtain pertinent information about the patientâ€™s medical condition  including signs and 
symptoms of illness, past and present medications, adverse effects, and medication 
adherence.  
D. Continue, renew or order medications based on the below criteria:  
a. The medication is on patientâ€™s medication list, or the Prescriberâ€™s notes o r other 
information documented in the patientâ€™s medical record indicate need for 
medication. Controlled substances (Schedule 2 -5) are not eligible under this 
Collaborative Pharmacy Practice Agreement.  
b. The patient must have been evaluated by a Prescriber in  the within the past 6 
months and enrolled in the study titled â€œImplementing the Los Angeles Barber -
Pharmacist Model of Hypertension Management in Nashville.â€  For patients who 
are seen annually, the patient must have been seen within the past [ADDRESS_242127] evaluates the 
following: (i) Presence of medication on the patient summary and/or clinical 
communication, and (ii) Presence of requisite diagnostic testing or completed visit 
information.  
d. The P harmacist may authorize renewals of an expi[INVESTIGATOR_202889] a Prescriber for up to 6 months.  
E. Authorize a change in prescriptions from 30 -day supply to 90 -day supply if requested by 
[CONTACT_202983].  
F. Authorize a new prescription for dose or dosage form changes.  
G. Authorize prescriptions for new medications that are documented in a patientâ€™s medical 
record but have not been generated as a prescription order.  
H. Discontinue medications causing clinically sig nificant drug interactions or adverse 
reactions and report all such occurrences in accordance with Section VIII.  
I. Educate patients concerning disease states, medication benefits and potential adverse 
effects and toxicity, and medication adherence.  
 
 
  
 
 
 
Protocol Version 2.0  Page 32 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Exhibit  B 
Quality Performance Review: Performance Metrics and Protocols  
Monthly Patient Record Review : 
 
Each month, the Collaborating Pharmacist will have 5% of treated patients reviewed by [CONTACT_202984](s) for the following quality indicators:  
â€¢ Documentation of provider referral  
â€¢ Correct drug/therapy  
â€¢ Correct dose  
â€¢ Correct duration  
â€¢ Any prescription errors  
â€¢ Adherence to practice agreement requirements  
The reviewing Physician will communicate their findings with the pharmacist, Pharmacy Director 
and the Medical Director. Opportunities for improvement will be identified and implemented as 
appropriate. Monthly reports will be collated and included in the Quarterly Quality Assessments.  
Quarterly Quality Assessment:  
The Pharmacist an d Medical Director meet quarterly in order to conduct a formal Quality 
Assessment of the Collaborative Pharmacy Practice Agreement in order to ensure that the patient 
care goals are being met and to identify opportunities for improvement. Such quarterly re view 
shall include consideration of any changes necessary to the Agreement, authorized formulary, 
and patient orders, patient education and medication adherence strategies, increased or 
improved monitoring of side effects and the need for further testing a nd screening. In addition, 
data will be collected from the patient medical record for accuracy and completeness of treatment 
plans, and to meet the quality metrics specified below.  
Quality Indicators:  
â€¢ Medication history updated  
â€¢ Medication reconciliation d ocumented  
â€¢ Allergy Documentation  
â€¢ Patient education documented  
â€¢ Summary of Adverse Drug Events reported  
â€¢ Quantitative review of number of patients cared for, new drug starts, drug or dose 
modifications, drug discontinuations and lab tests ordered  
â€¢ Any other qua lity assessments requested by [CONTACT_202985], 
Collaborating Providers, or Pharmacy, Therapeutics & Diagnostics Committee 
recommendations.  
The Quarterly Quality Assessment will be reviewed by [CONTACT_32335], Pharmacy Director and 
Medical Dire ctor. Opportunities for improvement will be identified and implemented as 
appropriate. These reports will be presented to the appropriate Pharmacy & Therapeutics 
Subcommittee and Pharmacy, Therapeutics & Diagnostics Committee and retained for at least 
ten (10) years.  
 
  
 
 
 
Protocol Version 2.0  Page 33 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Exhibit C  
 
Pharmacy Collaborative Practice Referral Template  
Collaborating Prescribers document a referral for each patient subject to the Collaborative 
Pharmacy Practice Agreement in accordance with Section VII of the Agreement, which is 
maintained in the patientâ€™s medical record , and the Collaborative Pharmacist provides services 
only to patients for whom a current patient  referral has been provided by a Collaborating 
Prescriber. All patient referrals containing a drug -specific, disease or condition -specific plan of 
care shall be made part of each patientâ€™s medical record . 
Collaborative Pharmacy Practice Referral â€“ Particip ation in â€œImplementing the Los Angeles 
Barber -Pharmacist Model of Hypertension Management in Nashvilleâ€ Study  
Collaborating Prescriber: ______________________  
Collaborating Pharmacist:   
Date of Service: TBD 
I hereby [CONTACT_202986] -named Pharmacist(s) to carry out the plan of care stated 
in the electronic medical record  for this patient per the criteria below.  
A. Provide patient care and drug therapy management services to those patients who are  
being managed for hypertension . 
B. Provide drug therapy management services with respect to the medications commonly 
used to treat the above listed disorders and order medication -related laboratory tests. 
These medications include angiotensin -converting enzy me inhibitors, angiotensin 
receptor blockers, calcium channel blockers, diuretics, beta -blockers, aldosterone 
blockers, central sympatholytics, alpha blockers, nitrates or other vasodilators. Order 
medication -related laboratory tests or obtain results from  a fingerstick using a CLIA -
waived point of care device. These laboratory tests may include blood 
chemistry/electrolyte panels or serum creatinine.  
C. Obtain pertinent information about the patientâ€™s medical condition including signs and 
symptoms of illness, past and present medications, adverse effects, and medication 
adherence.  
D. Continue, renew or order medications based on the below criteria:  
a. The medication is on patientâ€™s medication list, or the Prescriberâ€™s notes in the 
patientâ€™s medical record indicate ne ed for medication. Controlled substances 
(Schedule 2 -5) are not eligible under this Collaborative Pharmacy Practice 
Agreement  
 
b. The patient must have been evaluated by [CONTACT_202987] [ADDRESS_242128] evaluates the 
following: (i) Presence of medication on the patient summary and/or clinical 
communication, and (ii) Presence of requisit e diagnostic testing or completed visit 
information.  
 

  
 
 
 
Protocol Version 2.0  Page 34 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  d. The Pharmacist may authorize renewals of an expi[INVESTIGATOR_202889] a Prescriber for up to 6 months . 
 
E. Authorize a change in prescriptions from 30 -day supply to 90 -day supply if requested by 
[CONTACT_202983].  
 
F. Authorize a new prescription for dose or dosage form changes.  
 
G. Authorize prescriptions for new medications that are documented in a patientâ€™s medical 
record but have not been generated as a prescription order . 
 
H. Discontinue medications causing drug interactions or adverse reactions and report all 
such occurrences in accordance with Section VIII of the Agreement.  
 
I. Educate patients concerning disease states, medication benefits and potential adverse 
effects and t oxicity, and medication adherence.  
 
Electronically Signed by:  
 
  
  
 
 
 
[CONTACT_162797] 2.0  Page 35 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  APPENDIX 4: TENNESSEE STATE PHARMACY LAW ( CHAPTER 1140 -03) 
1In accordance with Tennessee State Pharmacy Law  and the Rules of the Tennessee Board of 
Pharmacy Chapter [ADDRESS_242129] has the following 
responsibilities for pharmaceutical care:  
(1) Patient counseling  
(a) Upon the receipt of a medical or prescription order and f ollowing a review of the patientâ€™s 
record, a pharmacist shall personally counsel the patient or caregiver â€œface -to- faceâ€ if the patient 
or caregiver is present. If the patient or caregiver is not present, a pharmacist shall make a 
reasonable effort to cou nsel through alternative means.  
(b) Alternative forms of patient information may be used to supplement, but not replace, face -to-
face patient counseling.  
(c) Patient counseling, as described herein, shall also be required for outpatients of hospi[INVESTIGATOR_202890].  
(d) Patient counseling as described in this rule shall not be required for inpatients of an institutional 
or long-term care facility .  
(e) Patient counseling shall cover matters, which in the exercise of the pharmacistâ€™s professional 
judgement, the pharmacist deems significant including:  
1. The name [CONTACT_203024];  
2. The dosage form, dose, route of administration, and dura tion of drug therapy;  
3. Special directions and precautions for preparation, administration, and use by [CONTACT_102];  
4. Common side effects or adverse effects or interactions and therapeutic contraindications 
that may be encountered, including their avoidance,  and the action required if they occur;  
5. Techniques for self -monitoring drug therapy;  
6. Proper storage;  
7. Prescription refill information; and  
8. Action to be taken in the event of a missed dose.  
(f)  Upon the receipt of a request for a refill of a medical or  prescription order, a pharmacist or a 
person designated by [CONTACT_202988]. Counseling as described in (e) above is not required unless requested by 
[CONTACT_202989].  
(g)  A pharmacist shall not be required to counsel a patient or caregiver when the patient or 
caregiver refuses such counseling.  
(2)  Patient Profiling.  
(a)  A patientâ€™s record system shall be maintaine d by [CONTACT_202990]. The patientâ€™s record system shall provide 
for the immediate retrieval of information necessary for the pharmacist to identify previously 
  
 
 
 
Protocol Version 2.0  Page 36 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  dispensed medical  and prescription orders at the time a medical or prescription order is 
presented.  
(b)  In order to effectively counsel patients, the pharmacist or a person designated by [CONTACT_202991], through communication with the patient, caregiver, or agent ma ke a reasonable 
effort to obtain, record, and maintain the following information for each patient of the individual 
pharmacy practice site.  
1. Name, address, telephone number.  
2. Date of birth (age), gender.  
3. An individual history where significant, i ncluding disease state or states, known allergies 
and drug reactions, and a comprehensive list of medications and relevant devices.  
4. Pharmacistâ€™s comments as deemed relevant. This may be done manually or by [CONTACT_22123].  
(3)  Drug Regimen Review.  
(a) A pharmacist shall be responsible for a reasonable review of a patientâ€™s record prior to 
dispensing each medical or prescription order. The review shall include evaluating the medical 
and prescription order for:  
1. Over -utiliza tion or under -utilization;  
2. Therapeutic duplication;  
3. Drug -disease contraindication;  
4. Drug -drug interactions;  
5. Incorrect drug dosage or duration of drug treatment;  
6. Drug -allergy interactions  
Footnotes:  
1The Tennessee Board of Pharmacy Standards of Practice  2017 Recommendations. 
https://publications.tnsosfiles.com/rules/1140/[ADDRESS_242130] accessed March 16, 2019. 
Protocol Version 2.0 Page 37 of112 CONFIDENTIAL 
Protocol Date: 02_2 5_2020APPENDIX 5: HYPERTENSION MANAGEMENT ALGORITHM 
Figure 1: Workflow
Figure 2. Hypertension standard of care treatment algorithm [references noted below]

  
 
 
 
Protocol Version 2.0  Page 38 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Figure 3. Sample Workflow  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  
 
 
 
Protocol Version 2.0  Page 39 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
Table 1. List of preferred drugs and doses*  
 Calcium 
channel 
blocker  Angiotensin -
converting -
enzyme 
inhibitor  Angiotensin 
receptor 
blocker  Thiazide 
diuretic  Vasodilating 
beta blocker  Aldosterone 
antagonist  Direct 
vasodilator  Central 
sympatholytic  Alpha -
blocker  
Low 
dose  2.5 mg 
amlodipi[INVESTIGATOR_050]  
30 mg 
nifedipi[INVESTIGATOR_050]  10 mg 
lisinopril  
10 mg 
benazepril  75 mg 
irbesartan  
20 mg 
telmisartan  0.625 mg 
indapamide  
12.5 mg 
chlorthalidone  6.25 mg 
carvedilol bid  12.5 mg 
spi[INVESTIGATOR_8407]  
25 mg 
eplerenone  25 mg 
hydralazine 
tid 0.5 mg 
guanfacine  1 mg 
terazosin  
Medium 
dose  5 mg 
amlodipi[INVESTIGATOR_050]  
60 mg 
nifedipi[INVESTIGATOR_050]  20 mg 
lisinopril  
20 mg 
benazepril  150 mg 
irbesartan  
40 mg 
telmisartan  1.25 mg 
indapamide  
25 mg 
chlorthalidone  12.5 mg 
carvedilol bid  25 mg 
spi[INVESTIGATOR_8407]  
50 mg 
eplerenone  50 mg 
hydralazine 
tid 1 mg 
guanfacine  5 mg 
terazosin  
High 
dose  10 mg 
amlodipi[INVESTIGATOR_050]  
90 mg 
nifedipi[INVESTIGATOR_050]  40 mg 
lisinopril  
40 mg 
benazepril  300 mg 
irbesartan  
80 mg 
telmisartan  2.5 mg 
indapamide  
50 mg 
chlorthalidone  25 mg 
carvedilol bid  50 mg+ 
spi[INVESTIGATOR_8407]  
50 mg+ 
eplerenone  100 mg 
hydralazine 
tid 2 mg 
guanfacine  10 mg 
terazosin  
 
* Daily dosing unless otherwise specified. Does not encompass all possible combinations and individual treatment selection can still be up to the clinician in 
partnership with the patient  
 
 
Table 2. Preferred Anti-hypertensive Drugs in Specific Conditions  
Condition  Drug(s)  
Hypertensive patients in general  CCB, ACE -I or ARB, D  
Hypertension in older patients  CCB, ACE -I or ARB, D  
Hypertension with left ventricular hypertrophy  ARB, D, CCB  
Hypertension in patients with diabetes mellitus  CCB, ACE -I or ARB, D  
Hypertension in patients with diabetic nephropathy  ARB, D  
Hypertension in patients with non -diabetic chronic kidney disease  ACE-I, BB, D  
Blood pressure reduction for secondary prevention of coronary events  ACE-I, CCB, BB, D  
Blood pressure reduction for secondary prevention of stroke  ACE-I + D, CCB  
Blood pressure management for patients with heart failure  D, BB, ACE -I, ARB, aldosterone antagonists  
ACE, angiotensin -converting enzyme; ARB, angiotensin receptor blocker; BB, beta -blocker; BP, blood pressure; CCB, calcium channel blocker; D,diuretic  
Adapted from the 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Mancia G. et al., J Hype rtens. 2013; 31:1281 -1356; and from 
Victor RG and Libby P: Systemic Hypertension: Management. Chp 44 In Braunwaldâ€™s Heart Disease , 10th Edition, DL Mann, DP Zipes, P Libby, and RO 
Bonow Eds., Elsevier, 2014.   
 
Footnotes: 
1 TG Pi[INVESTIGATOR_116281]., Call to action on use and reimbursement for home blood pressure 
monitoring: executive summary: a joint scientific statement from the American Heart Association, 
American Society of Hypertension, and Preventive Cardiovascular Nurses As sociation. 
Hypertension . 2008;521 -9. 
2 In accordance with multiple published hypertension treatment guidelines:  
â€¢ James PA, Oparil S, Carter BL et al. 2014 Evidence -Based Guideline for the Management 
of High Blood Pressure in Adults: Report From the Panel M embers Appointed to the Eighth 
Joint National Committee (JNC 8). JAMA 2013; 311(5), 507 -520 
â€¢ Weber MA, Schiffrin EL, White WB et al. Clinical Practice Guidelines for the Management 
of Hypertension in the community: a statement by [CONTACT_202992]. J Clin Hypertens (Greenwich ) 2014;16:14 -
26. 
  
 
 
 
Protocol Version 2.0  Page 40 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  â€¢ Go AS, Bauman M, King SM et al. An Effective Approach to High Blood Pressure Control: 
A Science Advisory From the American Heart Association, the American  College of 
Cardiology, and the Centers for Disease Control and Prevention. Hypertension 2013. : DA 
- 20131118  
â€¢ Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management 
of arterial hypertension: The Task Force for the management of  arterial hypertension of 
the European Society of Hypertension (ESH) and of the European Society of Cardiology 
(ESC). 2013. J.Hypertens. 31(7), 1281 -1357  
â€¢ Canadian Hypertension Education Program (CHEP) 2013 Recommendations.  2013. 12 -
26-2013.  
                http://www.hypertension.ca/chep. Last accessed 2 -9-2014.  
â€¢ Flack JM et al., Management of High Blood Pressure in Blacks: An Update of the 
International Society on Hypertension in Blacks Consensus Statement. Hypertension  
2010;56:780 -800.  
 
3 Combined use o f an ACE inhibitor and an ARB is contraindicated. ONTARGET Investigators, 
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high risk for 
vascular events. N Engl J Med 2008;358:[ADDRESS_242131] hypertensive patients require combination drug therapy to achieve blood pressure 
treatment goals. 
7Vasodilating beta blockers (e.g., carvedilol) are stronger blood pressure -lowering agents than 
standard beta blockers and do not elevate blood glucose. Unless contraindicated, beta blockers 
are first -line therapy fo r treatment of angina pectoris, after myocardial infarction, and heart failure.  
8Aldosterone blockers can be added if on thiazide and eGFR > 60 ml/min/1.73m2 and serum K < 
4.5. 
9Long -acting central sympatholytic agents (e.g., guanfacine) are preferred ove r short -acting 
clonidine to avoid rebound hypertension.  
10 Alpha blockers are indicated for men with protatism.  
11 Nitrates and vasodilators (e.g., hydralazine) are only used if other agents are not effective.       
 
Within each class, specific drugs pres cribed will vary somewhat based on individual insurance 
plans. Whenever possible, the pharmacist will prescribe high -dose pi[INVESTIGATOR_202891] -titration.  
 
Preferred drugs (once daily/long acting/evid ence -based/cost) : 
CCB - amlodipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_202892]- telmisartan, irbesartan  
ACEI - Lisinopril, benazepril  
Thiazide - indapamide, chlorthalidone  
Vasodilating beta -blocker - carvedilol  
Aldosterone antagonist -spi[INVESTIGATOR_8407], eplerenone  
Direct vasodilator - hydralazine  
Central sympatholytic - guanfacine  
Alpha -blocker - terazosin  
  
 
 
 
Protocol Version 2.0  Page 41 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  APPENDIX 6: STUDY FORMS , MATERIALS,  AND SURVEYS  
Appendix 6A: Barbershop/ Owner Letter of Collaboration  
 
MEMORANDUM OF AGREEMENT  
 
 
To: David Harrison, MD, FACC, FAHA  
  
  
 Nashville,  
 
 
Re: Cut Your Pressure Too: Implementing the Barbershop Blood Pressure in Nashville  
 
 
Dear [CONTACT_203150],  
 
My barbers and I understand that high blood pressure is a condition that can cause potentially 
deadly side effects that affects many of our customers.  I understand that you and your study 
team will approach customers in the barbershop to determine if they are eligible and would like to 
participate in the â€œCut Your Pressure Tooâ€ study and that many of the study procedures (including 
blood pressure measurements and interviews) will take place in the barbershop.  
 
As one of the studyâ€™s designated barbershop owners/managers, I certify that I have the authority 
to ag ree to allow the â€œCut Your Pressure Tooâ€ study to take place in the barbershop, specifically:  
 
Name [CONTACT_203025]: ____________________________________________  
 
Address of barbershop: ___________________________________________  
 
And I agree to:  
â€¢ Permit the barbershop and the barbers to participate fully in the â€œCut Your Pressure Tooâ€ 
study for the duration of the study, which I understand is approximately 9 â€“ 12 months.  
â€¢ Provide space in the barbershop and permit study staff to interview customers and 
conduct the study for the duration of the study.  
â€¢ Permit training for participating barbers to measure blood pressure and to participate in 
other study -related procedures in the barbershop.  
â€¢ Permit barbers to offer blood pressure checks to each study -eligible customer who 
chooses to join the study 1 to 2 times per month for 6 months when they come in for 
haircuts.  
â€¢ Permit the transmission of the blood pressure readings from the barbershop to the studyâ€™s 
Clinical Pharmacist and other approved study personn el. 
â€¢ Permit the posting of Role Model Stories (posters) in the barbershop of customers who 
have joined the study.  
â€¢ Display the Role Model Story posters in my barbershop for the duration of the study.  
â€¢ The shop owner will be compensated $1000 over the course o f the study, $[ADDRESS_242132] participant at the shop and the other $500 will be 
received at the completion of the shopâ€™s participation. This will be paid as a check.  

  
 
 
 
Protocol Version 2.0  Page 42 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  â€¢ During the study, I agree to permit the barbers who joi n the study to be compensated by 
[CONTACT_202993] a debit card or pre -paid gift card system. The system allows the 
research team to directly add payments to each barberâ€™s card instead of taking weeks to 
process a check and mail it. Payment requests will  be checked and approved within 48 â€“ 
hours on business days or by [CONTACT_202994] a weekend. The 
attached IRS W -[ADDRESS_242133] parties and will be kept confidential.  
â€¢ I understand that the â€œCut Your Pressure Tooâ€ research study has been reviewed and 
approved by [CONTACT_202995] 
I can request a copy of that approval from you.  
 
I understand and agre e to permit barbershop customers who choose to join the study to also be 
compensated by [CONTACT_202996] ($25 per haircut) and $10 per blood 
pressure check with up to 2 blood pressures checks per eligible customer per month (maximum 
of 12 measurements; 2 per month per customer). As the owner/manager of this barbershop, I 
certify that I have the authority and hereby [CONTACT_202997].  
 
Sincerely yours,  
 
 
Barbershop Manager/Owner ___________________________________ Date: ____________  
 
[CONTACT_203151] (Principal Investigator): _________________________ Date: ____________  
 
Authorized:  
 
, Director, Office of Contracts Management: _____________________  
 
Date: ______________  
 
 
  

  
 
 
 
Protocol Version 2.0  Page 43 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Appendix 6B: Study Surveys/forms / Appendix 6B.1: Screening Visit 1  
CUT YOUR PRESSURE TOO:  
The Nashville Barbershop Blood Pressure Study  
Screening Visit 1 Questionnaire  
 
â€¢ Introduction and Verbal Consent  
My name [CONTACT_832] _______ and I am offering free blood pressure screening to all men in the barbershop 
who are at least 35 years old as part of the Nashville Barbershop Blood Pressure Study being 
conducted by [CONTACT_202998]. Are you between 35 -79 years old (born 
anytime from 1940 to 1984) and interested in having your blood pressure checked?â€ [NOTE: 
SCRIPT ABOVE WILL NOT BE IN CAPI.  WILL BE ON INTRODUCTION CARD PROVIDED TO 
INTE RVIEWERS]  
â–ª IF PERSON AGREES, ASSIGN CASE ID Number  
â–ª REVIEW INFORMATION SHEET  
â–ª SEE INFORMATION SHEET ON TWO -STEP SCREENING PROCEDURES  
 
â€¢ Screening Questions  
 
1. What is your Date of Birth ?  Month _______Day_____Year_______  
 
[INTERVIEWER: IF CUSTOMER DOES NOT WANT TO PROVIDE FULL DATE OF BIRTH, 
ASK FOR JUST MONTH AND YEAR - ENTER -8 (REFUSED) FOR DAY]  
 
2. What is your name?   
Prefix ________  
First Name ________________   
Middle Name ___________________  
Last Name ________________  
Suffix______________  
Nickname___________  
 
3. How long have you been a customer at this barbershop?  
IF 1 YEAR OR MORE ENTER YEARS ONLY.  
IF 0-11 MONTHS, ENTER MONTHS ONLY.  
IF REFUSED ENTER -8 IN YEARS ONLY.  
IF DONâ€™T KNOW, ENTER -9 IN YEARS ONLY.  
___________ (Y EARS) (varname:  [CONTACT_203026])  
___________ (MONTHS) ONLY ENTER IF 0 -11 MONTHS  
(varname:  [CONTACT_203027])  
LESS THAN SIX MONTHS (INELIGIBLE)  
DONâ€™T KNOW  
REFUSED  
  
 
 
 
Protocol Version 2.0  Page 44 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  4. In the last 6 months, how many times did you come to this barbershop?   Would you sayâ€¦ 
[INTERVIEWER:   PROBE FOR BEST ESTIMATE, AS NEEDED] 
(varname:   [CONTACT_203028])  
a. 0 to 3 times,  
b. 4 to 6 times,  
c. 7 to 10 times,  
d. 11 to 15 times, or  
e. More than 15 times?  
  
DONâ€™T KNOW  
REFUSED  
[INELIGIBLE IF = (a)]  
 
5. Is this your main barbershop?  (varname: [CONTACT_203029] ) 
a. YES 
b. NO (INELIGIBLE)  
c. DONâ€™T KNOW  
d. REFUSED  
 
6. Do you have plans to change barbershops during the next 6 months?  (varname:  
[CONTACT_203030] ) 
a. YES (INELIGBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
7. Do you have plans to move away from the Nashville area during the next 6 months?  
(varname: [CONTACT_203031] ) 
a. YES (INELIGIBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
8. Do you consider yourself Black or African American?  (varname: [CONTACT_203032] ) 
a. YES 
b. NO (INELIGIBLE)  
c. DONâ€™T KNOW  
d. REFUSED  
 
9. Do you consider yourself to be of Hispanic, Latino, or Spanish origin? (varname: [CONTACT_203033] ) 
a. YES (INELGIBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
 
  
 
 
 
Protocol Version 2.0  Page 45 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  â€¢ CV Disease risk factors and comorbid conditions  
 
10. How tall are you?  (varname: [CONTACT_203034], HeightInches )      
[INTERVIE WER: ENTER -8 FOR REFUSED, ENTER -9 FOR DON'T KNOW]  
 
_________ Feet  _________ Inches     
DONâ€™T KNOW  
REFUSED  
 
11. How much do you weigh?  (varname: [CONTACT_5122] )  
 
[INTERVIEWER: ENTER -8 FOR REFUSED, ENTER -9 FOR DON'T KNOW]  
 
_________  LBS       
DONâ€™T KNOW  
REFUSED  
 
Next, I am going to ask you a few questions about your health.  
 
12. Has a doctor ever told you that you have â€¦ (check all that apply):  
a. High blood pressure (Hypertension) ( varname: C_HBP)  
b. Diabetes ( varname: C_Diabetes)  
c. Heart Attack ( varname: C_HeartAttack)  
d. Heart Failure [INTERVIEWER:  THIS MEANS ENLARGED AND WEAKENED HEART] 
(varname: C_HeartFailure)  
e. High Cholesterol ( varname: C_HighCholesterol)  
f. Enlarged Prostate ( varname: C_EnlargedProstate)  
g. Prostate Cancer ( varname: C_ProstateCancer)  
h. Stroke ( varname: C_Stroke)  
i. Asthma ( varname: C_Asthma)  
j. Sleep Apnea ( varname: C_SleepApnea)  
k. Kidney Disease ( varname: C_KidneyDisease)  
l. NONE OF THE ABOVE  (varname: C_None)  
m. DONâ€™T KNOW ( varname: C_DK)  
n. REFUSED ( varname: C_RF)  
 
â€¢ Medical Exclusion criteria  
 
13. a). Are you a kidney dialysis patient? (varname: [CONTACT_203035] ) 
a. YES (INELIGIBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
 
  
 
 
 
Protocol Version 2.0  Page 46 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  13. b). Have you ever received an organ transplant? (varname: [CONTACT_203036] ) 
a. YES (INELIGIBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
14. Are you currently  a cancer patient receiving chemotherapy? (varname: [CONTACT_203037] ) 
a. YES (INELIGIBLE)  
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
â€¢ Current Medications  
 
15. Are you taking any of the following PRESCRIPTION  medications? (check all that apply)  
a. Blood pressure pi[INVESTIGATOR_3353] (varname: M_BPPi[INVESTIGATOR_3353])  
b. Water pi[INVESTIGATOR_3353] (diuretics) (varname: M_WaterPi[INVESTIGATOR_3353])  
c. Insulin or pi[INVESTIGATOR_202893] (varname: M_Insulin)  
d. Pi[INVESTIGATOR_202894] (varname: M_Prostate)  
e. NONE OF THE ABOVE (varname: M_None)  
f. DONâ€™T KNOW (varname: M_DK)  
g. REFUSED (varname: M_RF)  
 
â€¢ Nocturia Questions  
 
16.  During the past [ADDRESS_242134] typi[INVESTIGATOR_202895], 
from the time you went to bed at night until the time you got up in the morning?  
[INTERVIEWER: SHOWCARD 1, PROBE FOR AN AVERAGE ON TYPI[INVESTIGATOR_202896]] 
(varname: [CONTACT_203038] ) 
 
[INTERVIEWER: SHOW CARD 1]  
a. 0 (SKIP TO BP MEASUREMENT)  
b. 1 
c. 2 
d. 3 
e. 4 
f. 5 OR MORE  
g. DONâ€™T KNOW (SKIP TO BP MEASUREMENT)  
h. REFUSED (SKIP TO BP MEASUREMENT)  
 
 
 
 
  
 
 
 
Protocol Version 2.0  Page 47 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  17. Now, using a scale from 0 to 10, with 0 indicating â€˜ not at all â€™ and 10 being â€˜ a great deal , 
please tell me how much does it bother you? (INTERVIEWER:  REPEAT QUESTION IF 
NEEDED: to get up to urinate, from the time you went to bed at night until the time you got 
up in the morning? )  INTERVIEWER:  SHOWCARD 2 (varname: [CONTACT_203038]2)  
 
[INTERVIEWER:  SHOW CARD 2]  
 
â˜     â˜     â˜     â˜     â˜     â˜    â˜    â˜     â˜     â˜     â˜        â˜     â˜    
            0      1       2      3       4      5     6      7      8       9      10   DK    REFUSED  
  Not at all         A great  
                             
â€¢ Blood Pressure Measurement   
Now, I will take your blood pressure readings. First,  I need to de termine your cuff size.  
 
18. MEASURE CUFF SIZE: (varname: [CONTACT_203039] ) 
SIZE CUFF [CHECK ONE]:  
a. SMALL (SMALL ADULT)  
b. MEDIUM (ADULT)  
c. LARGE (LARGE ADULT)  
 
NOTE:  CUFF SIZE WILL BE AUTOMATICALLY POPULATED FOR FUTURE VISITS.  
The machine will automatically take readings over the next few minutes.  
 INTERVIEWER: PLEASE HAVE PARTICIPANT SIT COMFORTABLY IN THE CHAIR  
â–ª WITH FEET FLAT ON THE FLOOR  
â–ª RIGHT ARM SUPPORTED AT HEART LEVEL  
â–ª WAIT [ADDRESS_242135] BEFORE TAKING BP READINGS  
â–ª TURN MACHINE AWAY FROM SUBJECTâ€™S VIEW  
â–ª INSTRUCT SUBJECT NOT TO TALK DURING BPâ€™S  
â–ª DO NOT SPEAK TO SUBJECT DURING BP  
â–ª AFTER STARTING BP READINGS, WALK AWAY FOR A FEW MINUTES, AND THEN 
CHECK TO SEE IF [ADDRESS_242136] BEEN COMPLETED  
 
[INTERVIEW ER: PROCEED TO CARETRENDS BLOOD PRESSURE PROCEDURE.]  
THE SUBJECT ID IS _______  
19.  [INTERVIEWER: HOW MANY BLOOD PRESSURE READINGS WERE TAKEN?] ______  
 
[INTERVIEWER: WAIT UNTIL BP MEASUREMENTS ARE COMPLETE, REMOVE BP  
CUFF, THEN CLICK NEXT TO RETRIEVE BP READINGS...]  
 
[INTERVIEWER: WAIT UNTIL BP MEASUREMENTS ARE COMPLETE, REMOVE BP 
CUFF, THEN CLICK NEXT TO RETRIEVE BP READINGS...]  
 
 
 
 
  
 
 
 
Protocol Version 2.0  Page 48 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  NOW TRYING TO RETRIE VE PRESSURE READINGS FROM THE SERVER.  
 
Systolic    Diastolic  
a. ___________    ___________  
 
b. ___________    ___________  
 
c. ___________    ___________  
 
d. ___________    ___________  
 
e. ___________    ___________  
 
f. ___________    ___________  
 
g. ___________    ___________  
 
h. ___________    ___________  
 
i. ___________    ___________  
 
j. ___________    ___________  
 
[INTERVIEWER: IF BP MEASUREMENTS ARE NOT DISPLAYED CLICK THE BUTTON 
BELOW. IF NO MEASURMENTS ARE RETURNED, CLICK NEXT TO PROCEED TO MANUAL 
BP ENTRY.]  
 
INTERVIEWER :  CHECK HERE TO FORCE MANUAL BP SCREEN TO DISPLAY ____ (NOTE 
THIS IS NEEDED IN CASE ALL OF CARETRENDS READINGS DO NOT TRANSMIT]  
 
IT WAS NOT POSSIBLE TO RETRIEVE THE READINGS FROM THE SERVIER.  PLEASE 
ENTER THEN MANUALLY [INTERVIEWER: ENTER BP READINGS IN THE ORDER TAKEN. 
NOTE: BP READINGS ARE LISTED IN REVERSE ORDER ON THE CARE TRENDS SCREEN.]  
 
READING DATE _______________________________________________  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Protocol Version 2.0  Page 49 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020    Systolic       Diastolic             Time  
1  ___________    ___________    ______________  
 
2. __________    ___________    ______________  
 
3. ___________    ___________    ______________  
 
4 ___________    ___________    ______________  
 
5. ___________    ___________    ______________  
 
6. ___________    ___________    ______________  
 
7. ___________    ___________    ______________  
 
8. ___________    ___________    ______________  
 
9. ___________    ___________    ______________  
 
10. ___________    ___________    ______________  
 
 
Compute average of BP Readings     Systolic_______   Diastolic ________  
 
On the participantâ€™s blood pressure card, record the following:  
â€¢ Participant name (from question 2) (CONFIRM NAME [CONTACT_203040])  
â€¢ Todayâ€™s date: ________________  
â€¢ Average blood pressure readings [BASED ON READINGS 3, 4, AND 5 (IF 5 OR MORE 
READINGS); BASED ON READINGS 3 AND 4 (IF 4 READINGS); MINIMUM OF 4 TOTAL 
READINGS]  
â€¢ IF LESS THAN [ADDRESS_242137] ANOTHER SESSION  
 
 
 
 
 
 
 
  
 
 
 
Protocol Version 2.0  Page 50 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  If the BP is  200/120 or higher , say the following:  
  
Your blood pressure is dangerously high  today and you need to seek medical attention without 
delay. Please call [ADDRESS_242138].  
â€¢ Statement was read to participant: Check YES . 
 
If the BP is  180/110 â€“ 199/119 , say the following:  
Your blood pressure is very high today.  Please see a doctor within the next [ADDRESS_242139].  
 
â€¢ Statement was read to participant: Check YES   
 
â€¢ Eligibility for 2nd Screening  Visit = YES if:  
 
o Age 35 to 79, AND   
o > [ADDRESS_242140] from Nashville area in next 6 months,  AND  
o Self-identified Black/African Americ an, AND  
o Not Hispanic, Latino or Spanish origin, AND  
o Not on kidney dialysis and not an organ transplant patient AND  
o Not a cancer patient receiving chemotherapy, AND  
o Average of systolic blood pressure readings >140 mmHg  
 
If participant is ineligible for seco nd screening , then say:  
 
Based on your information, you are not eligible for the next phase of this study. However, you 
may be eligible for future studies.  (varname: [CONTACT_203041]1 )  
 
[INTERVIEWER, PLEASE FOLLOW CONSENT PROCEDURES FOR FUTURE STUDIES]  
 
[INTERVIEWER: DID CUSTOMER CONSENT TO BEING IN FUTURE STUDIES AND FILL OUT 
CONTACT [CONTACT_7533]?]  
 
YES 
NO 
 
Thank you for taking the time today to help us learn more about high blood pressure in 
African American men. Here is a gift (water bottle) as a small token of our appreciation.  
 
  
 
 
 
Protocol Version 2.0  Page 51 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  IF CUSTOMER ASKS TO HAVE HIS BP READINGS, YOU WILL TAKE TWO BP READINGS 
AND PROVIDE THE SECOND READING TO HIM ON BP CARD. DO NOT START THE 
CARETRENDS PROGRAM ON THE LAPTOP IF VERY HIGH BP, READ SCRIPT FOR 
SEEKING MEDICAL CARE.  
 
IF PARTICIPANT MAY BE ELIGIBLE, BUT DID NOT PROVIDE INFORMATION FOR ONE OF 
THE ELIGIBILITY QUESTIONS, CAPI [INVESTIGATOR_202897] -ASK 
MISSING QUESTIONS  
 
If participant is eligible for second screening , say the following:  
 
Based on your in formation, you are eligible  for a 2nd screening visit.  We need a second visit to 
determine your eligibility for enrollment in the study.  
 
â— Appointment for Second Screening and Personal Contact [CONTACT_202999]â€™s make an appointment for your second screening visit. The sooner the better , even 
tomorrow would be great.  
 
[INTERVIEWER: THE LAST DAY IS [_________________]  
 
a. Schedule appointment for second screening (varname:  [CONTACT_203042])  
i. Day of Week:  
1. MONDAY  
2. TUESDAY  
3. WEDNESDAY  
4. THURSDAY  
5. FRIDAY  
6. SATURDAY  
7. SUNDAY  
8. REFUSED  
9. DONâ€™T KNOW  
 
ii. Date: ____/_____/_____ (varname:  [CONTACT_203043])  
 
iii. Time: _________ ( varname:  [CONTACT_203044])  
 
b. I would like to record your contact [CONTACT_203000] a reminder  
 
Your Home Phone #: (_____) ________ - __________  
Your Cell phone #: (_____) ________ - __________  
Your Work phone #: (_____) ________ - __________  
 
REFUSED PHONE  
 
NEED AT LEAST ONE ANSWER FOR PHONE OR REFUSED ABOVE  
TO CONTINUE  
 
 
  
 
 
 
Protocol Version 2.0  Page 52 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
Phone # of a close friend (_____) ________ - __________ Name ______  
Phone # of a relative: (_____) ________ - __________ Name _____  
Your Email: ______________@________________  
 
Your mailing address:  
Address  
Apt/Suite  
City 
State  
Zip Code  
REFUSED ADDRESS  
NEED ADDRESS OR REFUSED FILLED IN ABOVE TO CONTINUE  
 
c. What is the best way to contact [CONTACT_10825]? (varname: [CONTACT_203045] ) 
a. HOME PHONE  
b. CELL PHONE: CALL  
c. CELL PHONE: TEXT  
d. WORK PHONE  
e. FRIEND PHONE  
f. RELATIVE PHONE  
g. EMAIL  
h. MAIL  
i. OTHER   SPECIFY ____________  
j. DONâ€™T KNOW  
k. REFUSED  
 
d. What is the best time to reach you? (varname: [CONTACT_203046] ) 
a. MORNING  
b. AFTERNOON  
c. EVENING  
d. REFUSED  
e. DONâ€™T KNOW  
 
e. What are the best days to reach you? (varname: [CONTACT_203047] ) 
a. Monday -Friday  
                        b. Saturday -Sunday  
         c. DONâ€™T KNOW  
         d. REFUSED  
 
f. Who is your regular barber? (varname: [CONTACT_203048])  
____________________________________  
 
 
 
 
  
 
 
 
Protocol Version 2.0  Page 53 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   
DISPLAY PARTICIPANT NAME [CONTACT_203049][INVESTIGATOR_93601] B OTTLES, DOCTORâ€™S CARD, AND 
INSURANCE CARD TO BRING BACK NEXT TIME.  
 
GIVE APPOINTMENT CARD WITH THE FOLLOWING INFORMATION:  
APPOINTMENT DATE & TIME  
BARBERSHOP NAME [CONTACT_203050] [CONTACT_203001]. Here is a gift (water bottle) as a small token of our appreciation.  
 
ENTER COMMENTS, CORRECTIONS, OR ANY OTHER RELEVANT INFORMATION ABOUT 
THE RESP ONDENT: (varname: [CONTACT_203051]1)     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
Protocol Version 2.0  Page 54 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Appendix 6B.2: Screening Visit 2; Baseline (if enrolled)  
 
CUT YOUR PRESSURE TOO:  
The Nashville Barbershop Blood Pressure Study  
Health Questionnaire  
(Screening Visit 2/Baseline)  
Thank you for coming today. First, I need to bring up our information from your last visit and then 
I have a few questions. We can start now.  
 
CHECK ID AND NAME [CONTACT_203052], WERE FOUND ELIGIBLE, AND WERE SCHEDULED FOR SCREENING VISIT 2.  
 
INTERVIEWER:  PLEASE VERIFY THAT YOU HAVE SELECTED THE CORRECT SUBJECT  
 
SUBJECT NAME __________________________ __ 
 
SUBJECT ID ________________________________  
 
DATE OF BIRTH _____________________________  
 
BARBERSHOP ______________________________  
 
[REVIEW INFORMATION SHEET â€“ parts relevant to second screening]
 
Part 1: Blood Pressure Measurement  
 
[POPULATE  CUFF SIZE USED IN SCREENING VISIT 1]  
 
Now, I will take your blood pressure readings.  
 
The machine will automatically take readings over the next few minutes.  
  INTERVIEWER: PLEASE HAVE PARTICIPANT SIT COMFORTABLY IN THE CHAIR  
â–ª WITH FEET FLAT ON THE FLOOR  
â–ª RIGHT ARM SUPPORTED AT HEART LEVEL  
â–ª WAIT [ADDRESS_242141] BEFORE TAKING BP READINGS  
â–ª TURN MACHINE AWAY FROM SUBJECTâ€™S VIEW  
â–ª INSTRUCT SUBJECT NOT T O TALK DURING BPâ€™S  
â–ª DO NOT SPEAK TO SUBJECT DURING BP  
â–ª AFTER STARTING BP READINGS, WALK AWAY FOR A FEW MINUTES, AND THEN 
CHECK TO SEE IF [ADDRESS_242142] BEEN COMPLETED  
 
 
 
Protocol Version 2.0  Page 55 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  [INTERVIEWER: PROCEED TO CARETRENDS BLOOD PRESSURE PROCEDURE.]  
THE SUBJECT ID IS ________  
1.  [INTERVIEWER: HOW MANY BLOOD PRESSURE READINGS WE RE TAKEN?]  
______  
[INTERVIEWER: WAIT UNTIL BP  MEASUREMENTS ARE COMPLETE, REMOVE BP CUFF, 
THEN CLICK NEXT TO RETRIEVE BP READINGS...]  
 
NOW TRYING TO RETRIEVE PRESSURE READINGS FROM THE SERVER.  
 
Systolic    Diastolic  
a. ___________    ___________  
 
b. ___________    ___________  
 
c. ___________    ___________  
 
d. ___________    ___________  
 
e. ___________    ___________  
 
f. ___________    ___________  
 
g. ___________    ___________  
 
h. ___________    ___________  
 
i. ___________    _____ ______  
 
j. ___________    ___________  
 
[INTERVIEWER: IF BP MEASUREMENTS ARE NOT DISPLAYED CLICK THE BUTTON 
BELOW. IF NO MEASURMENTS ARE RETURNED, CLICK NEXT TO PROCEED TO MANUAL 
BP ENTRY.]  
 
INTERVIEWER:  CHECK HERE TO FORCE MANUAL BP SCREEN TO DISPL AY _ ___ (NOTE 
THIS IS NEEDED IN CASE ALL OF CARETRENDS READINGS DO NOT TRANSMIT]  
 
IT WAS NOT POSSIBLE TO RETRIEVE THE READINGS FROM THE SERVIER.  PLEASE 
ENTER THEN MANUALLY [INTERVIEWER: ENTER BP R EADINGS IN THE ORDER TAKEN. 
NOTE: BP READINGS ARE LISTED IN REVERSE ORDER ON THE CARE TRENDS SCREEN.]  
 
 
 
 
Protocol Version 2.0  Page 56 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  READING DATE _______________________________________________  
 
Systol ic    Diastolic    Time  
1 ___________    ___________    ______________  
 
2. __________    ___________    ______________  
 
3. ___________    ___________    ______________  
 
4. ___________    ___________    ______________  
 
5. ___________    ___________    ______________  
 
6. ___________    ___________    ______________  
 
7. ___________    ___________    ______________  
 
8. ___________    ___________    ______________  
 
9. ___________    ___________    ______________  
 
10. ___________    ___________    ______________  
 
 
Compute average of BP Readings Systolic  _______   Diastolic ________  
(varname: [CONTACT_203053], DiaAvg ) 
 
On the participantâ€™s blood pressure card, record the following:  
â€¢ Participant name (from question 2 ) (CONFIRM NAME [CONTACT_203040])  
â€¢ Todayâ€™s date: ________________  
â€¢ Average blood pressure readings [BASED ON READINGS 3, 4, AND 5 (IF 5 OR MORE 
READINGS); BASED ON READINGS 3 AND 4 (IF 4 READINGS ); MINIMUM  OF 4 TOTAL 
READINGS]  
 
â€¢ IF LESS THAN [ADDRESS_242143] ANOTHER SESSION  
 
 
 
 
 
 
 
 
 
Protocol Version 2.0  Page 57 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  If the BP is  200/120 or higher , say the following:  
  
Your blood pressure is dangerously high  today and you need to seek medical attention without 
delay. Please call [ADDRESS_242144].  
â€¢ Statement was read to participant: Check YES . 
 
If the BP is  180/110 â€“ 199/119 , say the following:  
 
Your blood pressure is very high today.  Please see a doctor within the next [ADDRESS_242145].  
 
â€¢ Statement was read to participant: Check YES   
 
Ineligible Participant:  
 
Based on your information, you are not eligible for the next phase of this study. However, you 
may be eligible for future studies. [INTERVIEWER:  PLEASE FOLLOW CONSENT 
PROCEDURES FOR FUTURE STUDIES]  
 
INTERVIEWER:  DID CUSTOMER CONSENT TO BEING IN FUTURE STUDIES AND FILL 
OUT CONTACT [CONTACT_7533].  
 
A. YES 
B. NO 
 
If yes, skip to gift card and then proceed to Registry Consent Form.  
If no, skip to gift card.  
 
Eligible Participant:  
 
IF PARTICIPANT PREVIOUSLY PROVIDED A HOME OR CELL PHONE AND ADDRESS, GO 
TO CO NSENT FOR RESEARCH AND USE AND DISCLOSURE OF INFORMTION.  ELSE, WE 
WILL DISPLAY SCREEN TO TRY AND OBTAIN THIS INFO AS FOLLOWS:  
 
IF NO PHONE, DISPLAY THE FOLLOWING:  
 
CONTACT [CONTACT_203002] 2.0  Page 58 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  [INTERVIEWER: WE DO NOT HAVE A HOME OR CELL PHONE NUMBER FOR THIS 
CUSTOMER  
 
We donâ€™t have a home or cell phone number on file for you.  Itâ€™s important we are able to 
contact [CONTACT_10825].  
 
Phone _________________________________  
Phone Type  
A. Home  
B. Mobile/Cell  
 
IF NO ADDRESS, DISPLAY THE FOLLOWING:  
Note  
 
[INTERVI EWER: WE DO NOT HAVE AN ADDRESS FOR THIS CUSTOMER  
 
We donâ€™t have a mailing address on file for you.  
 
Street Address [ADDRESS_242146] Address 2 _________________________________  
City ________________________________________ ___ 
State __________________________________________  
Zip ____________________________________________  
 
Your high blood pressure readings today indicate that you meet the requirements to go on to the 
6- month study. We would now like to take the opportunity to fully explain the study to you and 
obtain your informed consent in writing and gather some informat ion via a health questionnaire. 
May we proceed?   
 
INTERVIEWER CHECK:  
 
2. CONSENT FOR RESEARCH AND USE AND DISCLOSURE OF INFORMATION, 
including use of health information (HIPAA)  
 
____  CONSENT FOR RESEARCH AGREED (varname: [CONTACT_100522]_Research)  
  
3. INTERVIEWER CHECK  
 ____  PARTICIPANT SIGNED INFORMED CONSENT (varname: [CONTACT_203054])  
____  PARTICIPANT REFUSED    
  
4. REASONS FOR REF[LOCATION_003]L _____________________________________ (varname:  
[CONTACT_203055])  
 
If decline participation skip to gift card/compensation for screeni ng visit 2.  
 
 
 
 
Protocol Version 2.0  Page 59 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Part 1: Health and Healthcare Questions  
CV Disease and Risk  
 
5. Has anyone in your immediate family (for example, mother, father, sister, brother, or 
children) ever had high blood pressure? (varname: [CONTACT_203056])  
a. YES 
b.  NO  
c. DONâ€™T KNOW  
d. REFUSED  
 
6. Have you smoked at least 100 cigarettes or cigars in your lifetime? (varname: 
[CONTACT_203057]100)  
a. YES 
b.  NO    (SKIP TO QUESTION 8)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 8)  
d. REFUSED   (SKIP TO QUESTION 8)  
 
7. Have you smoked at all in the last year? (varname: [CONTACT_203058])  
a. YES  
b.  NO    (SKIP TO QUESTION 7.3)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 7.3)  
d. REFUSED    (SKIP TO QUESTION 7.3)  
 
7.1. Have you smoked at all in the last 30 days? (varname: 
[CONTACT_203059]30Days)  
a. YES 
b. NO (SKIP TO QUESTION 7.3)  
c. DONâ€™T KNOW (SKIP TO QUESTION 7.3)  
d. REFUSED (SKIP TO QUESTION 7.3)  
 
7.2. During the past 30 days, on average, about how many cigarettes did you 
smoke in a day?  (varname: [CONTACT_203060]30)  
 
__________   (SKIP TO QUESTION 8)  
 
DONâ€™T KNOW   (SKIP TO QUESTION 8)  
REFUSED   (SKIP TO QUESTION 8)  
 
7.3. On average, over the entire time you have smoked, how many cigarettes 
have you usually smoked per day? (varname: 
[CONTACT_203061])  
 
___________  
 
DONâ€™T KNOW  
REFUSED  
 
Protocol Version 2.0  Page 60 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  7.4. How old were you when you quit smoking?  (varname: [CONTACT_203062])  
 
____________   
 
DONâ€™ T KNOW  
  REFUSED  
 
Perceived Health  
 
8. Overall, how would you rate your health?  Would you sayâ€¦ (varname: [CONTACT_203063])  
a. Excellent  
b. Very Good  
c. Good  
d. Fair 
e. Poor  
f. Very Poor  
g. DONâ€™T KNOW  
h. REFUSED  
 
BP Medication Adherence (Adherence to Refills and Medications (ARMS) Scale   
9. Have you ever had blood pressure medication prescribed or refilled? (varname: 
[CONTACT_203064])
a. YES 
b. NO   (SKIP TO QUESTION 22)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 22)  
d. REFUSED   (SKIP TO QUESTION 22)  
  
BP Medication Adherence (Adherence to Refills and Medications (ARMS) Scale)  
(Kripalani, Risser, Gatti, & Jacobson, 2009)  
 
It is common for people to miss taking their medicine from time to time, or to take it differently than 
prescribed. I would like to as k you about how you actually take your blood pressure medicines. There 
are no right or wrong answers. For each question, please answer â€œnone of the time,â€ â€œsome of the 
time,â€ â€œmost of the time,â€ or â€œall of the time.â€  
 
10. How often do you forget to take your m edicine? (varname: [CONTACT_203065] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
 
 
 
 
 
 
Protocol Version 2.0  Page 61 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  11. How often do you decide not to take your medicine? (varname: [CONTACT_203066] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
12. How often do you forget to get prescriptions filled? (varname: [CONTACT_203067]_fill ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
13. How often do you run out of medicine? (varname: [CONTACT_203068] )  
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
14.  How often do you skip a dose of your medicine before you go to the doctor?  
(varname_ doseskip ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
15. How often do you miss taking your medicine when you feel better? (varname: [CONTACT_203069] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
16. How often do you miss taking your medicine when you feel sick?  (varname: [CONTACT_203070] )  
(1) None  
(2) Some  
(3) M ost 
(4) All  
DONâ€™T KNOW  
REFUSED  
 
 
 
 
Protocol Version 2.0  Page 62 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  17. How often do you miss taking your medicine when you are careless? (varname: [CONTACT_203071] )   
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
18. How often do you change the dose of your medicines to suit your needs (like when you take 
more or less pi[INVESTIGATOR_202898]â€™re supposed to)?  (varname: [CONTACT_203072] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
19. How often do you forget to take your medicine when you are supposed to take it more than  
      once a day? (varname: [CONTACT_203073]_med_multiple )   
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
20. How often do you put off refilling your medicines be cause they cost too much money?   
      (varname: [CONTACT_203074] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
21. How often do you plan ahead and refill your medicines before they run out?  
(varname: [CONTACT_203075] ) [PROGRAMMING: THESE ANSWERS ARE NUMBERED IN 
REVERSE ON PURPOSE]    
(4) None  
(3) Some  
(2) Most  
(1) All  
DONâ€™T KNOW  
REFUSED  
 
 
 
 
 
 
 
 
Protocol Version 2.0  Page 63 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  Patient Assessment of Chronic Illness Care (PACIC). (Glasgow RE et al. Med Care 2005; 43(5): 
436-44) 
 
22. Have you received medical care for high blood pressure in the last 6 months? (varname: 
[CONTACT_203076]6Mos)  
a. YES 
b. NO   (SKIP TO QUESTION  43) 
c. DONâ€™T KNOW   (SKIP TO QUESTION  43) 
d. REFUSED   (SKIP TO QUESTION  43) 
 
INTRO A: Staying  healthy  can be difficult  when  you have  a chronic  condition . We would  like to learn  
about  the type of help with your condition you get from your health  care team. This might include your 
regular doctor, his or her nurse, or a physicianâ€™s assistant who treats your illness.  Your answers will 
be kept confidential and will not be shared wit h your physician or clinic.  
INTERVIEWER:  USE SHOWCARD 3  
Think about the following statement:  
Over  the past 6 months, when I received  care for my chronic conditions , I was : 
23. Asked  for my  ideas  when  we made a  treatment  plan.  (varname: [CONTACT_203077])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T  KNOW  
g. REFUSED  
 
24. Given  choices  about  treatment  to think  about. (varname: [CONTACT_203078])  
a.  None  of the time  
b.  A little of the time 
c.  Some  of the time 
d.  Most  of the time 
e.  Always  
f.  DONâ€™T KNOW  
g. REFUSED  
 
25. Asked  to talk about  any problems  with my medicines  or their effects. (varname: [CONTACT_203079])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
 
 
Protocol Version 2.0  Page 64 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  26. Given  a written  list of things  I should  do to improve  my health . (varname: [CONTACT_203080])  
a. None  of the time  
b.  little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
27. Satisfied  that my care was well-organized. (varname: [CONTACT_203081])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
28. Shown  how what I did to take care of myself  influenced  my condition. (varname: [CONTACT_203082])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
29. Asked  to talk about  my goals  in caring  for my condition. (varname: [CONTACT_203083])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
30. Helped  to set specific  goals  to improve  my eating  or exercise. (varname: [CONTACT_203084])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
 
 
 
Protocol Version 2.0  Page 65 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  31. Given  a copy  of my treatment  plan. (varname: [CONTACT_203085])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
32. Encouraged  to go to a specific  group  or class  to help me cope  with my chronic  condition. 
(varname: [CONTACT_203086])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
33. Asked  questions,  either  directly  or on a survey,  about my  health  habits. (varname: 
[CONTACT_203087])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
34. Sure,  that my doctor or,  nurse  thought  about  my values,  beliefs,  and traditions  when  they 
recommended  treatments  to me? (varname: [CONTACT_203088])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
35. Helped  to make  a treatment  plan that I could  carry  out in my daily life. (varname: [CONTACT_203089])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
36. Helped  to plan ahead  so I could  take care of my condition  even  in hard times. (varname: 
[CONTACT_203090])  
 
 
Protocol Version 2.0  Page 66 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
37. Asked  how my chronic  condition  affects  my life. (varname: [CONTACT_203091])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
38. Contact[CONTACT_203003] a visit to see how things  were  going. (varname: [CONTACT_203092][INVESTIGATOR_530])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
39. Encouraged  to attend  programs  in the community  that  could  help me . (varname: [CONTACT_203093])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
40. Referre d to a dietitian,  health  educator,  or counselor . (varname: [CONTACT_203094])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
41. Told how my visits  with other  types  of doctors, like an eye doctor or other specialist  helped  my 
treatment. (varname: [CONTACT_203095])  
a. None  of the time  
 
 
Protocol Version 2.0  Page 67 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
42. Asked  how my visits  with other  doctors  were  going. (varname: [CONTACT_203096])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
Demographics: Asked only on Screening Day 2  
43. Are you currently married, or living with someone as if you were married (i.e. domestic 
partner)? (varname: [CONTACT_203097] ) 
a. YES 
b. NO 
c. DONâ€™T KNOW  
d. REFUSED  
 
44. What is the highest degree or level of education you have completed? (varname: 
[CONTACT_203098])  
a. LESS THAN HIGH SCHOOL  
b. HIGH SCHOOL GRADUATE (INCLUDES EQUIVALENCY/GED)  
c. SOME COLLEGE OR ASSOCIATEâ€™S DEGREE  
d. BACHELORâ€™S DEGREE  
e. GRADUATE OR PROFESSIONAL DEGREE.  
 
45. Which  of the income group  best represents your annual household income?  
       (INTERVIEWER: SHOW CARD 4) (varname: [CONTACT_203099])  
a. $0-$15,999  
b. $16,000 -$24,999  
c. $25,000 -$39,999  
d. $40,000 -$49,999  
e. $50,000 -$74,999  
f. $75,000 -$99,999  
g. $100,00 or more  
h. DONâ€™T KNOW    
i. REFUSED  
 
 
 
46/47 . How many people , including yourself, do you support with this income? [NOTE IF 
DK/REF ABOVE, CHANGE QUESTION AS FOLLOWS: How many people, including 
yourself are supported with your annual household income?]  This could incl ude your 
 
 
Protocol Version 2.0  Page 68 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020  spouse, your significant other, children, parents, or other household members. (varname: 
[CONTACT_203100] ) 
 
[INTERVIEWER: ENTER -8 FOR REFUSED, ENTER -9 FOR DON'T KNOW]  
 
_________ people  (UNLESS 45 = DK/REF, SKIP TO 48)  
DONâ€™T KNOW   (SKIP TO 48)  
REFUSED   (SKIP TO 48)  
 
48. [ONLY DISPLAY IN CAPI [INVESTIGATOR_202899] 45 = DONâ€™T KNOW OR REFUSED] Is  your total 
household income above  or below  (pi[INVESTIGATOR_202900])? (varname: [CONTACT_203101] ) 
   Family of 1 - $13,000  
Family of 2 - $15,500  
Family of 3 - $19,500  
Family of 4 - $23,500  
Family of 5 - $27,500  
Family of 6 - $32,000  
Family of 7 - $36,000  
Family of 8 - $40,000  
DONâ€™T KNOW  
REFUSED
a. Above   
b. Belo w  
 
Access to Healthcare: Asked only at Screening Day [ADDRESS_242147] let me ask you,  
 
49. Is there one medical clinic or office building that you go to for routine medical care? 
(varname: [CONTACT_203102] )  
a. YES 
b. NO   (SKIP TO QUESTION 51)  
c. DONâ€™T KNOW   (SKIP TO QUESTION 51)  
d. REFUSED   (SKIP TO QUESTION 51)  
 
50. I will need to record information about t he medical clinic or office building:  
a. Name [CONTACT_203103]: _____________________________  
b. Street Address: ________________________  
c. City:  ______________________  
d. Phone #: (_____) ________ - _________  
e. Fax #: (_____) ________ - _________  
f. Email: __________ ___________________  
 
51. Is there one particular doctor whom you see for routine medical care? (varname: 
[CONTACT_203104] ) 
a. YES 
b. NO   (SKIP TO QUESTION 53 IF QUESTION 49= YES; ELSE SKIP TO QUESTION 54)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 53 IF QUESTION 49= YES; ELSE SKIP TO QUESTION 54)  
d.   REFUSED        (SKIP TO QUESTION 53 IF QUESTION 49= YES; ELSE  SKIP TO QUESTION 54)
 
 
  
Protocol Version 2.0  Page 69 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   52. Doctorâ€™s Contact [CONTACT_7171]  
a. Doctorâ€™s name: _____________________________  
b. Doctorâ€™s phone #: (_____) ________ - _________  
c. Fax #: (_____) ________ - _________  
d. Email:  _____________________________  
 
53.  In the last [ADDRESS_242148] you visited this doctor or clinic for 
medical care?  _______________ (varname: [CONTACT_203105]3Mos ) 
DONâ€™T KNOW  
REFUSED  
 
54. Did you bring your medical insurance card with you today? (varname: [CONTACT_203106] ) 
a. YES 
b. NO   (SKIP TO QUESTION 56)  
c. DONâ€™T KNOW   (SKIP TO QUESTION 56)  
d. REFUSED   (SKIP TO QUESTION 56)  
  
55. Now I will record your medical insurance information from your medical insurance card. 
[Examples: Anthem Blue Cross Blue Shield HMO, Medicare Part A/B]  
a. Insurance carrier: _____________________________ (varname: [CONTACT_203107] ) 
b. Plan Type (HMO, PPO, EPO, POS): _____________________________ (varname: 
[CONTACT_203108] ) 
 
56. Have you needed to go to the Emergency Room or been hospi[INVESTIGATOR_202901] 3 
months? (varname: [CONTACT_89482]3Mos)  
a. YES 
b. NO   (SKIP TO QUESTION 60)  
c. DONâ€™T KNOW   (SKIP TO QUESTION 60)  
d. REFUSED   (SKIP TO QUESTION 60)  
 
57. For what reason? ____________________________________________ (varname: 
[CONTACT_203109])  
 
58. What date were you in the hospi[INVESTIGATOR_202902]?    Month __ Day ___ Year  
(varname: [CONTACT_203110])  
 
59. What hospi[INVESTIGATOR_202903]? _ ______________________ (varname: 
[CONTACT_203111])  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Protocol Version 2.0  Page 70 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   60.Have you experienced any of the fo llowing in the past 3 months? (CHECK ALL THAT 
APPLY) [ INTERVIEWER: USE SHOWCARD 6]  
â–¡ A) swollen ankles (varname: [CONTACT_107285]_SwollenAnkles, RS_SwollenAnkles ) 
â–¡ B) swollen gums (varname: [CONTACT_107285]_SwollenGums, RS_SwollenGums ) 
â–¡ C) swelling of the lips, throat, and/or tongue (varname: [CONTACT_107285]_SwelingLips, RS_SwelingLips ) 
â–¡ D) hair loss (varname: [CONTACT_107285]_HairLoss, RS_HairLoss ) 
â–¡ E) erectile dysfunction (varname: [CONTACT_107285]_ErectileDisfunction, RS_ErectileDisfunction ) 
â–¡ F) gout (varname: [CONTACT_107285]_Gout, RS_Gout ) 
â–¡ G) difficulty breathing or wheezing (varname: [CONTACT_107285]_DifficultyBreathing, 
RS_DifficultyBreathing ) 
â–¡ H) dry cou gh (varname: [CONTACT_107285]_DryCough, RS_DryCough ) 
â–¡ I) depression (varname: [CONTACT_107285]_Depression, RS_Depression ) 
â–¡ J) headache (varname: [CONTACT_107285]_Headache, RS_Headache ) 
â–¡ K) palpi[INVESTIGATOR_814] (feeling that your heart is pounding or racing) (varname: [CONTACT_107285]_Palpi[INVESTIGATOR_814], 
RS_Palpi[INVESTIGATOR_814] ) 
â–¡ L) breast tenderness or enlargement (varname: [CONTACT_107285]_BreastTenderness, 
RS_BreastTenderness ) 
â–¡ M) excessive sleepi[INVESTIGATOR_202904] ( varname: [CONTACT_107285]_ExcessiveSleepi[INVESTIGATOR_008], 
RS_ExcessiveSleepi[INVESTIGATOR_008] ) 
â–¡ N) dizziness (varname: [CONTACT_107285]_Dizziness, RS_Dizziness ) 
â–¡ O) skin rash (varname: [CONTACT_107285]_SkinRash, RS_SkinRash ) 
â–¡ NONE OF THE ABOVE  (SKIP TO QUESTION 75) (varname: [CONTACT_107285]_None ) 
â–¡ DONâ€™T KNOW   (SKIP TO QUESTION 75) (varname: [CONTACT_107285]_DK ) 
â–¡ REFUSED    (SKIP TO QUESTION 75)  (varname: [CONTACT_107285]_RF ) 
 
60-74: 
[NOTE:  ONE QUESTION FOR EACH ITEM IDENTIFIED IN 60]   How severe was the reaction?  
Was itâ€¦ [FOR EACH ITEM FOR 60, THIS QUESTION SHOULD INCLUDE BOTH THE ITEM 
AND THE LETTER, SO THAT WE CAN REFER TO SHOWCARD IF NEEDED]  
â–¡ Mild (I did not need to see my doctor)  
â–¡ Moderate (I needed to see my doctor)  
â–¡ Severe (I was hospi[INVESTIGATOR_057])  
â–¡ Life -threatening (I was hospi[INVESTIGATOR_202905] (ICU))  
â–¡ DONâ€™T KNOW  
â–¡ REFUSED  
AFTER ALL ITEMS ARE ASKED GO TO QUESTION 75  
 
Current Medications  
75. Are you taking any prescription medication for any medical condition? (varname: 
[CONTACT_203112] ) 
a. Yes 
b. No   (SKIP TO QUESTION 97)  
c. DONâ€™T KNOW   (SKIP TO QUESTION 97)   
d. REFUSED   (SKIP TO QUESTION 97)   
 
76. Did you bring the medication with you today?  (varname: [CONTACT_203113] ) 
a. YES (SKIP TO QUESTION 80)  
b. NO 
 
 
 
  
Protocol Version 2.0  Page 71 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   [If No, ask: When is the earliest you can bring in your medication? The sooner the better, 
even tomorrow would be great.  
[INTERVIEW:  THE LAST DAY IS ___]  
 
â–ª Schedule follow up date:  
77. Day of Week:  
a. MONDAY  
b. TUESDAY  
c. WEDNESDAY  
d. THURSDAY  
e. FRIDAY  
f. SATURDAY  
g. SUNDAY  
 
78. Date: ____/_____/_____  
 
79. Time: ____________________  
                        
INTERVIEWER TO BREAK OFF HERE AND  RE-START AFTER PARTICIPANT BRINGS 
MEDS.  
 
80-95.  Now I will record the name, dose, how often you are to take the medication(s) you 
brought in today and prescriber information.  
 
ALLOW FOR DROPDOWN LIST FOR BP MEDICATIONS.  OTHER NON -BP MEDICATIONS 
JUST ALLOW FOR ENTERING NAME [CONTACT_203114] (OTHER NON -BP ME DS IS FIRST 
OPTION ON LIST).  
 
FOR EACH BP MED: [CAN PUT IN UP TO 15 MEDS â€”QUESTIONS 80 -95] 
 
(varname: [CONTACT_203115]01 â€“ DrugMed15 ) 
(varname: [CONTACT_203116]01 â€“ NonBPMed15 ) 
 
DOSE ________________ (varname: [CONTACT_203117]01 â€“ DoseMed15 ) 
 
DOSE PER DAY (response options = Â½, 1, 2, 3, weekly, every night    
(varname: [CONTACT_203118]01 â€“ DosePerDayMed15 ) 
 
PRESCRIBER FIRST NAME ______________________  
(varname: [CONTACT_203119]01 â€“ PrescriberFirstMed15 ) 
 
PRESCRIBER LAST NAME _____________________ __ 
(varname: [CONTACT_203120]01 â€“ PrescriberLastMed15 ) 
 
96. MEDICATION COMMENTS ( varname:  [CONTACT_203121] ) 
____________________________________________________  
 
TEMPORARY ID CARD â€“ FILL OUT TEMPORARY ID CARD  
ONLY INTERVEIWER :  LET CUSTOMER KNOW HE SHOULD RECEIVE HIS PERMANENT 
STUDY ID CARD BY [CONTACT_203004] 2 WEEKS.   
 
 
  
Protocol Version 2.0  Page 72 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   DISPLAY PARTICIPANT NAME [CONTACT_203122] --Gift Cards  
 
Thank you for taking the time to participate in the second screening. You will be receiving $[ADDRESS_242149] or check.  
 
[INTERVIEWER: AFTER ENTERING GIFT CARD NUMBER, VERIFY THAT THE NUMBERS 
WERE ENTERED CORRECTLY]  
 
ENTER GIFT CARD NUMBER(S)  
 
GIFT CARD FOR SCREEDING VISIT COMPLET ION  # ____________ (varname: 
[CONTACT_203123])  
 
GIFT CARD FOR ENROLLED PATIENT Baseline Encounter completed  # ____________ 
(varname: [CONTACT_203124])  
 
Screening Visit 2/Baseline  
 
EXPLAIN NEXT STEPS â€” 
 
MENTION ABOUT STUDY PHARMACIST AND BARBER V ISITS.  REFER TO STUDY 
INCENTIVES. BARBER WILL TAKE THEIR BLOOD PRESSURE DURING REGULAR 
HAIRCUT VISITS [ADDRESS_242150], HE WILL GET 
A $[ADDRESS_242151] A BRIEF PHONE INTERVIEW.  HE WILL GET A $[ADDRESS_242152] FOR 
COMPLETING THE PHONE INTERVIEW.  ALSO, THERE WILL BE AN IN PERSON 
INTERVIEW AT THE BARBERSHOP AFTER 6 MONTHS.  FOR COMPLETING THE 6 
MONTH VISIT, PARTICIPANT GETS A $[ADDRESS_242153].  
 
Thank you for your time.  
 
[INTERVIEWER:  ENTER COMMENTS, CORRECTIONS, OR ANY OTHER RELEVANT 
INFORMATION ABOUT THE RESPONDENT]  
 
 
 
 
IMPORTANT --AFTER EXITING INTERVIEW VERIFY CONTACT [CONTACT_203005] (FOR EXAMPLE, ADDRESS, PHONE 
NUMBERS)  
 
 
 
  
Protocol Version 2.0  Page 73 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6B.3: 3 -Month Telephone Survey  
 
Three -Month Telephone Interview  
 
PHONE NUMBERS [DISPLAY NUMBERS IN SMS]  
CONTACT [CONTACT_203006] [DISPLAY CONTACT [CONTACT_203007] 3 MONTH CALL]  
Subject Name:  [DISPLAY PARTICIPANT NAME]  
Best Way to Contact:  [DISPLAY BEST WAY TO CONTACT]  
Best Time to Contact:  [DISPLAY BEST TIME TO CONTACT]  
Best Days to Contact:  [DISPLAY BEST DAYS TO CONTACT]  
 
May I speak with <NAME [CONTACT_203125]>?  
RESULTS :  
Data Collector : 
             Codes                  Interim Labels  
1 RNA  
2 Refusal  
5 AM [GO TO SCRIPT]  
7 Questionable ring  
8 Problem  
11 Number resolved  
31 Busy  
32              Dead Air                       
41 General Call Back/ General 
Appt.  
[ADDRESS_242154] Appt.  
61 Language/Hearing -Speech  
ND Deceased  
NP Not available  
 
 
Answering Machine : 
Hello, my name [CONTACT_832] [NAME [CONTACT_203126]] from Vanderbilt University Medical Center. Iâ€™m 
calling {FIRST NAME} {LAST NAME} regarding a 5 -minute telephone interview for the 
Barbershop Study. Upon completion of the interview, you will receive $15.  Please call us at 
[PHONE NUMBER] . Thank you.  
COMMENT ABOUT AM MESSAGE 
_________________________________________________  
 
1. Just to confirm, am I speaking with [NAME] ? 
â˜YES ............................ 1   (GO TO RESULT )  
â˜NO .............................. 2   (GO TO RESULT)  
 
Hi, my name [CONTACT_832] [NAME [CONTACT_203126]].  
I am a telephone interviewer with the Nashville Barbershop Blood Pressure Study in which 
you are participating at [NAME [CONTACT_203127]]  
This is a quick five -minute call to ask a few health questions.  
By [CONTACT_203008],  you will receive $15.  
 
 
  
Protocol Version 2.0  Page 74 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   2. In the last [ADDRESS_242155] you seen a doctor about your blood pressure? (varname:  
[CONTACT_203128] ) 
a. Yes 
b. No {GO TO QUESTION 4}  
c. DONâ€™T KNOW {GO TO QUESTION 4}  
d. REFUSED {GO TO QUESTION 4}  
 
3. In the last 3 months, how many times did you see a doctor about your blood pressu re? 
______________ (varname:  [CONTACT_203129] ) 
DONâ€™T KNOW  
REFUSED  
 
4. [IF DOCTOR AVAILABLE FROM PREVIOUS SURVEY] In the last [ADDRESS_242156] you 
changed the doctor who is responsible for managing your blood pressure?  The 
Doctor's name [CONTACT_203130] [NAME [CONTACT_203131]]:  
[IF NO DOCTOR AVAILABLE FROM PREVIOUS SURVEY] Do  you have a doctor 
who is responsible for managing your blood pressure?   (varname:  [CONTACT_203132] ) 
a. Yes 
b. No {GO TO QUESTION 6}  
c. DONâ€™T KNOW {GO TO QUESTION 6}  
d. REFUSED {GO TO QUESTION 6}  
 
5.  What is this doctor's name? (SubjectProtected)  
Doctorâ€™s Name _____________  
Phone ____________________  
Fax # _____________________  
E-mail ____________________  
 
6. [IF INSURANCE INFO AVAILABLE FROM PREVIOUS SURVEY] In the last [ADDRESS_242157] you changed your medical insurance plan?  The insurance information I have on 
file is: [NAME [CONTACT_203133]] (varname:  
[CONTACT_203106] ) 
a. Yes   
b. No 
c. DONâ€™T K NOW  
d. REFUSED  
 
[IF NO INSURANCE INFO AVAILABLE FROM PREVIOUS SURVEY] Do you have 
medical insurance?  
 
7. What is the insurance carrier?  
Insurance Carrier:  _____________________ (varname:  [CONTACT_203107] ) 
Plan Type: (HMO, PPO, EPO, POS) ___________________ (varname:  
[CONTACT_203108] ) 
 
8. Now I would like to confirm contact [CONTACT_203009].  
[IF ADDRESS IN SMS] Do you have a new mailing address? The address(es) we 
have on file is [(ADDRESSES) IN SM S] 
 
 
  
Protocol Version 2.0  Page 75 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   [IF NO ADDRESS IN SMS] Can  I get a mailing address we could use to contact [CONTACT_203010]? (varname:  [CONTACT_203134] ) 
a. Yes 
b. No [GO TO QUESTION 9a]  
 
9. What is your mailing address? (SubjectProtected)  
Address_________________________  
Apt/Suite _____________ ___________  
City ______________________  
State _________________________  
Zip ____________________________  
 
9a. [INTERVIEWER: FOR EACH PHONE LISTED BELOW:  
 
READ THE STATEMENT WITH PHONE NUMBER  
IF PHONE NUMBER NO LONGER CURRENT, SELECT EDIT, SET PHONE 
STATUS TO INACTIVE, AND SELECT UPDATE.]  
 
[HOME/WORK/ CELL]  Can you still be reached at ________?  
 
[FRIEND/ RELATIVE]  I have ___________ as a friend/ relativeâ€™s  number who 
will know how to contact [CONTACT_10825]. Is this still current?  
 
[INTERVIEWER: AFTER VERIFYING EACH PHONE ASK:]  
Other than the phone numbers I just asked about, are there any other phone 
numbers you can be reached at?   
 
[INTERVIEWER: IF YES: CLICK NEW PHO NE, ENTER INFORMATION, AND 
CLICK ADD.] (SubjectProtected)  
  
10. [IF E -MAIL ADDRESS IN SMS] Do you have a new e -mail address? The e -mail 
address I have on file is: [E -MAIL ADDRESS IN SMS]?  
[IF NO E -MAIL ADDRESS in SMS] Do you have an e -mail address we could use  to 
contact [CONTACT_10825]? (varname:  [CONTACT_203135] ) 
a. Yes 
b. No {GO TO QUESTION 12}  
c. REFUSED  
 
11. What is your e -mail address? ___________________________ _ (SubjectProtected)  
 
12.   Now I have a few questions about your health.  
In the past [ADDRESS_242158] you needed to go to the Emergency Room or been 
hospi[INVESTIGATOR_057]? (varname:  [CONTACT_89482]3Mos ) 
a. Yes 
b. No {GO TO QUESTION 16}  
c. DONâ€™T KNOW {GO TO QUESTION 16}  
d. REFUSED {GO TO QUESTION 16}  
 
 
 
 
  
Protocol Version 2.0  Page 76 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   13. For what reason? ___________________ _ (varname:  [CONTACT_203109] ) 
 
14. What date were you in the hospi[INVESTIGATOR_202902]?    Month __ Day ___ Year  
(varname:  [CONTACT_203110] ) 
 
15. What hospi[INVESTIGATOR_202903]? _ ___________ (varname:  [CONTACT_203111] ) 
 
16. In the past [ADDRESS_242159] you experienced any of the following? (C HECK ALL THAT 
APPLY)  
â–¡ swollen ankles (varname: ( a) AR _SwollenAnkles, RS_AR_SwollenAnkles ) 
â–¡ swollen gums (varname: (b) AR_SwollenGums, RS_SwollenGums ) 
â–¡ swelling of the lips, throat, and/or tongue (varname: (c) AR_SwelingLips, 
RS_SwelingLips ) 
â–¡ hair loss (varname: (d) AR_HairLoss, RS_HairLoss ) 
â–¡ erectile dysfunction (varname: (e) AR_ErectileDisfunction, 
RS_ErectileDisfunction ) 
â–¡ gout (varname: (f) AR_Gout, RS_Gout ) 
â–¡ difficulty breathing or wheezing (varname: ( g) AR _DifficultyBreathing, 
RS_DifficultyBreathing ) 
â–¡ dry cough (varname: (h) AR_DryCough, RS_DryCough ) 
â–¡ depression (varname: (i) AR_Depression, RS_Depression ) 
â–¡ headache (varname: (j) AR_Headache, RS_Headache ) 
â–¡ palpi[INVESTIGATOR_814] (feeling that your heart is poundin g or racing) (varname: (k) 
AR_Palpi[INVESTIGATOR_814], RS_Palpi[INVESTIGATOR_814] ) 
â–¡ breast tenderness or enlargement (varname: (l) AR_BreastTenderness, 
RS_BreastTenderness ) 
â–¡ excessive sleepi[INVESTIGATOR_202904] (varname: (m) AR_ExcessiveSleepi[INVESTIGATOR_008], 
RS_ExcessiveSleepi[INVESTIGATOR_008] ) 
â–¡ dizziness (varname: (n) AR_Dizziness, RS_Dizziness ) 
â–¡ skin rash (varname: (o) AR_SkinRash, RS_SkinRash ) 
â–¡ NONE OF THE ABOVE (varname: (p) AR_None ) 
â–¡ DONâ€™T KNOW (varname: (q) AR_DK ) 
â–¡ REFUSED (varname: (r) AR_RF ) 
 
16-30. IF YES FOR ANY ITEM IN 1 6, ASK ABOUT IT:  
Think about yourâ€¦  
[NAME [CONTACT_203136] 16] How severe was the reaction?  Was it?  
â–¡ Mild (I did not need to see my doctor about the reaction)  
â–¡ Moderate (I needed to see my doctor about the reaction)  
â–¡ Severe (I was hospi[INVESTIGATOR_057])  
â–¡ Life -threatening ( I was hospi[INVESTIGATOR_202905] (ICU))  
â–¡ DONâ€™T KNOW  
â–¡ REFUSED  
 
32. Do you have any additional comments? (varname:  M3_EndComment ) 
 
_____________________________________________________________________  
 
Thank you for your time. I will be calling you again in 3 months to schedule your six -month in -
person visit with me or one of my fellow research coordinators . 
 
 
  
Protocol Version 2.0  Page 77 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6B.4: 6 -Month Vis it Survey  
 
CUT YOUR PRESSURE TOO:  
The Nashville Barbershop Blood Pressure Study  
Health Questionnaire  
(6-Month Follow -up) 
 
Thank you for coming today. First, I need to bring up our information from your last visit and 
then I have a few questions. We can start now.  
 
CHECK ID AND NAME [CONTACT_203137]:  PLEASE VERIFY THAT YOU HAVE SELECTED THE CORRECT 
SUBJECT  
 
SUBJECT NAME ____________________________  
 
SUBJECT ID ________________________________  
 
DATE OF BIRTH _____________________________  
 
BARBERSHOP ______________________________  
 
[INSTR UCT PARTICIPANT  TO USE THE RESTROOM BEFORE YOU GET STARTED]  
 
Blood Pressure Measurement  
 
Now, I will take your blood pressure readings.  
 
[POPULATE  CUFF SIZE USED IN SCREENING VISIT 1]  
 
The machine will automatically take readings over the next few minutes.  
â€¢ [INTERVIEWER: PLEASE HAVE PARTICIPANT SIT COMFORTABLY IN THE CHAIR  
â€¢ WITH FEET FLAT ON THE FLOOR,  
â€¢ RIGHT ARM SUPPORTED AT HEART LEVEL,  
â€¢ WAIT [ADDRESS_242160] BEFORE TAKING BP READIN GS,  
â€¢ TURN MACHINE AWAY FROM SUBJECTâ€™S VIEW,  
â€¢ INSTRUCT SUBJECT NOT TO TALK DURING BPâ€™S, AND  
â€¢ DO NOT SPEAK TO SUBJECT DURING BP.  
â€¢ AFTER STARTING BP READINGS, WALK AWAY FOR A FEW MINUTES, AND 
THEN CHECK TO SEE IF [ADDRESS_242161] BEEN COMPLETED. ] 
 
[INTERVIEWER: PROCEED TO CARETRENDS BLOOD PRESSURE PROCEDURE.]  
THE SUBJECT ID IS ________  
 
1. INTERVIEWER: HOW MANY BLOOD PRESSURE READINGS WERE TAKEN?]  
______  
 
 
 
 
  
Protocol Version 2.0  Page 78 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   [INTERVIEWER: WAIT UNTIL BP  MEASUREMENTS ARE COMPLETE, REMOVE BP 
CUFF, THEN CLICK NEXT TO RETR IEVE BP READINGS...]  
 
NOW TRYING TO RETRIEVE PRESSURE READINGS FROM THE SERVER.  
 
Systolic    Diastolic  
a. ___________    ___________  
 
b. ___________    ___________  
 
c. ___________    ___________  
 
d. ___________    ___________  
 
e. ___________    ___________  
 
f. ___________    ___________  
 
g. ___________    ___________  
 
h. ___________    ___________  
 
i. ___________    ___________  
 
j. ___________    ___________  
 
 
[INTERVIEWER: IF BP MEASUREMENTS ARE NOT DISPLAYED CLICK THE BUTTON 
BELOW. IF NO MEASURMENTS ARE RETURNED, CLICK NEXT TO PROCEED TO 
MANUAL BP ENTRY.]  
INTERVIEWER:  CHECK HERE TO FORCE MANUAL BP SCREEN TO DISPLAY _ ___ 
(NOTE THIS IS NEEDED IN CASE ALL OF CARETRENDS READINGS DO NOT 
TRANSMIT]  
 
IT WAS NOT POSSIBLE TO RETRIEVE THE READINGS FROM THE SERVIER.  PLEASE  
ENTER MANUALLY.  
 
[INTERVIEWER: ENTER BP READINGS IN THE ORDER TAKEN. NOTE: BP READINGS 
ARE LISTED IN REVERSE ORDER ON THE CARE TRENDS SCREEN.]  
 
REASONS FOR MANUAL BP ENTRY 
_____________________________________________  
 
READING DATE 
_______________________________________________ _______________  
 
 
 
 
 
 
 
 
 
  
Protocol Version 2.0  Page 79 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020    
 
 
Systolic    Diastolic    Time  
1. ___________    ___________    ______________  
 
2. __________    ___________    ______________  
 
3. ___________    ___________    ______________  
 
4. ___________    ___________    ______________  
 
5. ___________    ___________    ______________  
 
6. ___________    ___________    ______________  
 
7. ___________    ___________    ______________  
 
8. ___________    ___________    ______________  
 
9. ___________    ___________    ______________  
 
10. ______ _____    ___________    ______________  
 
Compute average of BP Readings   Systolic  _______   Diastolic ________  
(varname: [CONTACT_203053], DiaAvg ) 
 
On the participantâ€™s blood pressure card, record the following:  
â€¢ Participant name (from question 2 ) (CONFIRM NAME [CONTACT_203040])  
â€¢ Todayâ€™s date: ________________  
â€¢ Average blood pressure readings [BASED ON READINGS 3, 4, AND 5 (IF 5 OR 
MORE READINGS); BASED ON READINGS 3 AND 4 (IF 4 READINGS ); MINIMUM  
OF 4 TOTAL READINGS]  
â€¢ IF LESS THAN [ADDRESS_242162] ANOTHER SESSION  
 
If the BP is  200/120 or higher , say the following:  
  
Your blood pressure is dangerously high  today and you need to seek medical attention 
without delay. Please call [ADDRESS_242163].  
â€¢ Statement was read to participant: Check YES . 
 
If the BP is  180/110 â€“ 199/119 , say the following:  
 
Your blood pressure is very high today.  Please see a doctor within the next [ADDRESS_242164].  
 
 
 
  
Protocol Version 2.0  Page 80 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   â€¢ Statement was read to participant: Check YES  
 
 
â€¢  Part 1: Health and Healthcare Questions  
 
Patient Satisfaction with Chronic Disease Care Scale  
 
For the past [ADDRESS_242165] bring medical care to your barbershop 
working with you and your doctor or the study doctor to control your blood pressure.  This is a 
new program and we appreciate your confidential feedback on how itâ€™s working.  
Patient Assessment of Chronic Illness Care (PACIC). (Glasgow RE et al. Med Care 2005; 
43(5): 436 -44) 
 
INTRO: Staying  healthy  can be difficult  when  you have  a chronic  condition . We would  like to 
learn  about  the type of help with your condition you get from your health  care team. This might 
include your regular doctor, his or her nurse, or a physicianâ€™s assistant who treats your illness.  
Your answers will be kept confidential and will not be shared wit h your physician or clinic.  
INTERVIEWER:  USE SHOWCARD 3  
 
Think about the following statement:  
 
Over  the past 6 months, when I received  care for my chronic conditions , I was : 
 
2. Asked  for my  ideas  when  we made a  treatment  plan.  (varname: [CONTACT_203077])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
3. Given  choices  about  treatment  to think  about. (varname: [CONTACT_203078])  
a.  None  of the time  
b.  A little of the time 
c.  Some  of the time 
d.  Most  of the time 
e.  Always  
f.  DONâ€™T KNOW  
h. REFUSED  
 
4. Asked  to talk about  any problems  with my medicines  or their effects. (varname: 
[CONTACT_203079])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
  
Protocol Version 2.0  Page 81 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020    
 
 
5. Given  a written  list of things  I should  do to improve  my health . (varname: [CONTACT_203080])  
a. None  of the time  
b.  little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
6. Satisfied  that my care was well-organized. (varname: [CONTACT_203081])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always   
f. DONâ€™T KNOW  
g. REFUSED  
 
7. Shown  how what I did to take care of myself  influenced  my condition. (varname: 
[CONTACT_203082])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
8. Asked  to talk about  my goals  in caring  for my condition. (varname: [CONTACT_203083])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
9. Helped  to set specific  goals  to improve  my eating  or exercise. (varname: [CONTACT_203084])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
 
  
Protocol Version 2.0  Page 82 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   10. Given  a copy  of my treatment  plan. (varname: [CONTACT_203085])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
11. Encouraged  to go to a specific  group  or class  to help me cope  with my chronic  condition. 
(varname: [CONTACT_203086])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
12. Asked  questions,  either  directly  or on a survey,  about my  health  habits. (varname: 
[CONTACT_203087])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
13. Sure  that my doctor or,  nurse  thought  about  my values,  beliefs,  and traditions  when  they 
recommended  treatments  to me? (varname: [CONTACT_203088])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
14. Helped  to make  a treatment  plan that I could  carry  out in my daily life. (varname: [CONTACT_203089])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
  
Protocol Version 2.0  Page 83 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   15. Helped  to plan ahead  so I could  take care of my condition  even  in hard times. (varname: 
[CONTACT_203090])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
16. Asked  how my chronic  condition  affects  my life. (varname: [CONTACT_203091])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
17. Contact[CONTACT_203003] a visit to see how things  were  going. (varname: [CONTACT_203092][INVESTIGATOR_530])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
18. Encouraged  to attend  programs  in the community  that  could  help me . (varname: 
[CONTACT_203093])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
19. Referred  to a dietitian,  health  educator,  or counselor . (varname: [CONTACT_203094])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
 
 
 
 
 
 
  
Protocol Version 2.0  Page 84 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   20. Told how my visits  with other  types  of doctors, like an eye doctor or other specialist  helped  
my treatment. (varname: [CONTACT_203095])  
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
21. Asked  how my visits  with other  doctors  were  going. (varname: [CONTACT_203096])   
a. None  of the time  
b. A little of the time 
c. Some  of the time 
d. Most  of the time 
e. Always  
f. DONâ€™T KNOW  
g. REFUSED  
 
DEMOGRPAHICS  
 
CV DISEASE AND RISK  
 
INTERVIEWER: We asked you similar questions when you entered the study, and we very 
much appreciate you answering again even if your answers have not changed.  
 
22.1) Have you smoked at least 100 cigarettes or cigars in your lifetime? (varname: 
[CONTACT_203057]100 ) 
a. YES 
b.  NO   (SKIP TO QUESTION 23)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 23)  
d. REFUSED  (SKIP TO QUESTION 23)  
 
22.2) Have  you smoked at all in the last year? (varname: [CONTACT_203058] ) 
a. YES  
b.  NO   (SKIP TO QUESTION 22.5)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 22.5)  
d. REFUSED  (SKIP TO QUESTION 22.5)  
 
22.3) Have you smoked at all in the last 30 days? (varname: [CONTACT_203059]30Days ) 
a. YES 
b. NO (SKIP TO QUESTION 22.5)  
c. DONâ€™T KNOW (SKIP TO QUESTION 22.5)  
d. REFUSED (SKIP TO QUESTION 22.5)  
 
22.4) During the past 30 days, on average, about how many cigarettes did you smoke in a 
day? (varname: [CONTACT_203060]30 )  
______   (SKIP TO QUESTION 23)  
            DONâ€™T KNOW (SKIP TO QUESTION 23)  
REFUSED (SKIP TO QUESTION 23)  
 
 
  
Protocol Version 2.0  Page 85 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   22.5)  On average, over the entire time you have smoked, how many cigarettes have you 
usually smoked per day? (varname: [CONTACT_203061] ) 
_______  
DONâ€™T KNOW  
REFUSED  
 
22.6)  How old were you when you quit smoking? (varname: [CONTACT_203062] ) 
____________   
DONâ€™T KNOW  
REFUSED  
 
Perceived Health  
 
23. Overall, how would you rate your health?  Would you sayâ€¦ (varname: [CONTACT_203063])  
a. Excellent  
b. Very Good  
c. Good  
d. Fair 
e. Poor  
f. Very Poor  
g.   DONâ€™T KNOW  
h. REFUSED  
 
BP Medication Adherence Adherence to Refills and Medications ( ARMS) Scale ; (Adherence to 
Refills and Medications (ARMS) Scale; Kripalani, Risser, Gatti, & Jacobson, 2009)  
 
It is common for people to miss taking their medicine from time to time, or to take it differently 
than prescribed. I would like to ask you about how you actually take your blood pressure 
medicines. There are no right or wrong answers. For each question, please answer â€œnone of 
the time,â€ â€œsome of the time,â€ â€œmost of the time,â€ or â€œall of the time.â€  
 
24. How often do you forget to take your medicine? (varname: [CONTACT_203065] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
25. How often do you decide not to take your medicine? (varname: [CONTACT_203066] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
 
 
 
 
 
 
  
Protocol Version 2.0  Page 86 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   26. How often do you forget to get prescriptions filled? (varname: [CONTACT_203067]_fill ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
27. How often do you run out of medicine? (varname: [CONTACT_203068] )  
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
28. How often do you skip a dose of your medicine before you go to the doctor? 
(varname_ doseskip ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
29. How often do you miss taking your medicine when you feel better? (varname: 
[CONTACT_203069] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
30. How often do you miss taking your medicine when you feel sick?  (varname: [CONTACT_203070] )  
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
31. How often do you miss taking your medicine when you are careless? (varname: 
[CONTACT_203071] )   
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
 
 
  
Protocol Version 2.0  Page 87 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   32. How often do you change the dose of your medicines to suit your needs (like when you take 
more or less pi[INVESTIGATOR_3353] t han youâ€™re supposed to)?  (varname: [CONTACT_203072] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
33. How often do you forget to take your medicine when you are supposed to take it more than 
once a day? (varname: [CONTACT_203073]_med_multiple )   
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
34. How often do you put off refilling your medicines because t hey cost too much money?  
(varname: [CONTACT_203074] ) 
(1) None  
(2) Some  
(3) Most  
(4) All  
DONâ€™T KNOW  
REFUSED  
 
35. How often do you plan ahead and refill your medicines before they run out? (varname: 
[CONTACT_203075] ) [PROGRAMMING:  THESE ANSWERS ARE NUMBERED IN REVERSE 
ON PURPOSE]    
(4) None  
(3) Some  
(2) Most  
(1) All  
DONâ€™T KNOW  
REFUSED  
 
Frequency of MEDICAL APPOINTMENTS FOR HYPERTENSION  
 
36.  In the last [ADDRESS_242166] you had a medical appointment for your blood pressure?  This 
could have been with your personal doctor, heart specialist, nurse, or pharmacist. 
(varname:  [CONTACT_203128] ) 
a. YES 
b. NO {GO TO QUESTION 38}  
c. DONâ€™T K NOW {GO TO QUESTION 38}  
d. REFUSED {GO TO QUESTION 38}  
 
37.  In the last [ADDRESS_242167] you had? ______________ 
(varname:  [CONTACT_203129] ) 
  DONâ€™T KNOW  
  REFUSED  
 
 
  
Protocol Version 2.0  Page 88 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Nocturia  
 
38.  During the past 30 days , how many times per night did you typi[INVESTIGATOR_202895], 
from the time you went to bed at night until the time you got up in the morning? 
(varname: [CONTACT_203038] ) 
 
[SHOWCARD 1 - PROBE FOR AN AVERAGE OR TYPI[INVESTIGATOR_202906]]  
 
a. 0    (GO TO QUESTION 40)  
b. 1 
c. 2 
d. 3 
e. 4 
f. 5 OR MORE  
g. DONâ€™T KNOW  (GO TO QUESTION 40)  
h. REFUSED   (GO TO QUESTION 40)  
 
39. Now using a scale from 0 to 10, with 0 indicating â€˜ not at allâ€™  and 10 being â€˜ a great deal , 
please tell me how much does it bother you? (REPEAT QUESTION IF NEEDED: to get 
up to urinate, from the time you went to bed at night until the time you got up in the 
morning?) (varname: [CONTACT_203038]2)  
 
  [SHOW CARD 2]  
 
â˜     â˜     â˜     â˜     â˜     â˜    â˜    â˜     â˜     â˜     â˜        â˜     â˜    
[ADDRESS_242168] you visited a doctor or clinic for any type of 
medical care? _____ (varname: [CONTACT_203105]3Mos)  
 
ADVERSE EVENTS  
41. Have you needed to go to the Emergency Room or been hospi[INVESTIGATOR_202901] 3 
months? (varname: [CONTACT_89482]3Mos)  
a. YES 
b. NO  (SKIP TO QUESTION 45)  
c. DONâ€™T KNOW  (SKIP TO QUESTION 45)  
d. REFUSED  (SKIP TO QUESTION 45)  
42.  For what reason? ____________________________________  
      (varname: [CONTACT_203109])  
43. What date were you in the hospi[INVESTIGATOR_202902]?    Month __ Day ___ Year     
      (varname: [CONTACT_203110])  
 
44. What hospi[INVESTIGATOR_202903]? _ ____________ __________  
     (varname: [CONTACT_203111])  
 
 
 
 
 
  
Protocol Version 2.0  Page 89 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   45. Have you experienced any of the following in the past 3 months? (CHECK ALL THAT 
APPLY) [ INTERVIEWER: USE SHOWCARD 6]  
â–¡ A) swollen ankles (varname: [CONTACT_107285]_SwollenAnkles, RS_SwollenAnkles ) 
â–¡ B) swollen gums (varname: [CONTACT_107285]_SwollenGums, RS_SwollenGums ) 
â–¡ C) swelling of the lips, throat, and/or tongue (varname: [CONTACT_107285]_SwelingLips, 
RS_SwelingLips ) 
â–¡ D) hair loss (varname: [CONTACT_107285]_HairLoss, RS_HairLoss ) 
â–¡ E) erectile dysfunction (varname: [CONTACT_107285]_ErectileDisfunc tion, RS_ErectileDisfunction ) 
â–¡ F) gout (varname: [CONTACT_107285]_Gout, RS_Gout ) 
â–¡ G) difficulty breathing or wheezing (varname: [CONTACT_107285]_DifficultyBreathing, 
RS_DifficultyBreathing ) 
â–¡ H) dry cough (varname: [CONTACT_107285]_DryCough, RS_DryCough ) 
â–¡ I) depression (varname: [CONTACT_107285]_Depression, RS_Depression ) 
â–¡ J) headache (varname: [CONTACT_107285]_Headache, RS_Headache ) 
â–¡ K) palpi[INVESTIGATOR_814] (feeling that your heart is pounding or racing) (varname: [CONTACT_107285]_Palpi[INVESTIGATOR_814], 
RS_Palpi[INVESTIGATOR_814] ) 
â–¡ L) breast tenderness or enlargement (varname: [CONTACT_107285]_BreastTenderness, 
RS_BreastTen derness ) 
â–¡ M) excessive sleepi[INVESTIGATOR_202904]  (varname: [CONTACT_107285]_ExcessiveSleepi[INVESTIGATOR_008], 
RS_ExcessiveSleepi[INVESTIGATOR_008] ) 
â–¡ N) dizziness (varname: [CONTACT_107285]_Dizziness, RS_Dizziness ) 
â–¡ O) skin rash (varname: [CONTACT_107285]_SkinRash, RS_SkinRash ) 
â–¡ NONE OF THE ABOVE  (SKIP TO QUESTION 60) (varname: [CONTACT_107285]_None ) 
â–¡ DONâ€™T KNOW   (SKIP TO QUESTION 60) (varname: [CONTACT_107285]_DK ) 
â–¡ REFUSED   (SKIP TO QUESTION 60)  (varname: [CONTACT_107285]_RF ) 
 
45-59. 
[NOTE:  ONE QUESTION FOR EACH ITEM IDENTIFIED IN 45]   Was itâ€¦ [FOR EACH ITEM 
FOR 45, THIS QUESTION SHOULD INCLUDE BOTH THE ITE M AND THE LETTER, SO 
THAT WE CAN REFER TO SHOWCARD IF NEEDED]  
â–¡ Mild (I did not need to see my doctor)  
â–¡ Moderate (I needed to see my doctor)  
â–¡ Severe (I was hospi[INVESTIGATOR_057])  
â–¡ Life -threatening (I was hospi[INVESTIGATOR_202905] (ICU))  
â–¡ DONâ€™T KNOW  
â–¡ REFUSED  
AFTER ALL ITEMS ARE ASKED GO TO QUESTION 60  
 
Current Medications  
 
60. Are you taking any prescription medication for any medical condition? (varname: 
[CONTACT_203112])  
e. Yes 
f. No   (GO TO QUESTION 78)  
g. DONâ€™T KNOW   (GO TO QUESTION 78)   
h. REFUSED   (GO TO QUESTION 78)   
 
62. Did you bring the medication with you today?  (varname: [CONTACT_203113] ) 
a. YES   
b. NO   (GO TO QUESTION 78)  
 
 
  
Protocol Version 2.0  Page 90 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   63-76. Now I will record the name, dose, how often you are to take the medication(s) you 
brought in today and prescriber information.  
 
ALLOW FOR DROP DOWN LIST FOR BP MEDICATIONS.  OTHER NON -BP 
MEDICATIONS JUST ALLOW FOR ENTERING NAME [CONTACT_203114] (OTHER NON -
BP MEDS IS FIRST OPTION ON LIST).  
 
FOR EACH BP MED: [CAN PUT IN UP TO 15 MEDS â€”QUESTIONS 62 -76] 
 
(varname: [CONTACT_203115]01 â€“ DrugMed15 ) 
(varname: [CONTACT_203116]01 â€“ NonBPMed15 ) 
 
DOSE ________________ (varname: [CONTACT_203117]01 â€“ DoseMed15 ) 
 
DOSE PER DAY (response options = Â½, 1, 2, 3, weekly, every night    
(varname: [CONTACT_203118]01 â€“ DosePerDayMed15 ) 
 
PRESCRIBER FIRST NAME ______________________  
(varname: [CONTACT_203119]01 â€“ Prescribe rFirstMed15 ) 
 
PRESCRIBER LAST NAME _______________________  
(varname: [CONTACT_203120]01 â€“ PrescriberLastMed15 ) 
 
 
77. MEDICATION COMMENTS ( varname:  [CONTACT_203121] ) 
 
 
The following questions refer to your experiences as a barbershop patron in this 
Barber -Physician -Pharmacist Program.  In answering these questions, please consider 
your barber measuring your blood pressure as well as your pharmacist meeting with 
you as pa rt of this program.  
 
78. What impressed you most about the Program? (varname:  [CONTACT_203138] ) 
 
79. What did you like least about the Program? (varname:  [CONTACT_203139] ) 
 
80. What recommendations would you offer to improve the Program? (varname:  
[CONTACT_203140] ) 
 
81. Do you know of any other barbershops that would be interested in participating in the 
program?  [INTERVIEWER, IF YES, RECORD THE NAMES AND LOCATIONS OF 
BARBERSHOPS]  (varname:  [CONTACT_203141] ) 
 
Gift card  
 
Thank you for taking the time to participate in the 6 Month Follow -up. 
 
(CHECK SMS TO SEE IF PARTICIPANT HAS BEEN ISSUED A RELOADABLE DEBIT 
CARD.  IF HE HAS A DEBIT CARD TELL HIM THAT $[ADDRESS_242169] 
BY [CONTACT_203011].)  
 
 
 
  
Protocol Version 2.0  Page 91 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Here is a $[ADDRESS_242170]  ($[ADDRESS_242171]) for  completing the 6-
month  Interview and for bringing your prescription pi[INVESTIGATOR_182586].  
 
[IF PARTICIPANT HAS debit card, ENTER NONE FOR GIFTCARD NUMBER]  
 
GIFTCARD  #______________________________ (varname: [CONTACT_203142])  
 
[INTERVIEWER, PLEASE FOLLOW CONSENT PROCEDURES FOR FUTURE STUDIES]  
 
[INTERVIEWER: DID CUSTOMER CONSENT TO BEING IN FUTURE STUDIES AND FILL 
OUT CONTACT [CONTACT_7533]?]  
(varname: [CONTACT_203041]1 )  
 
YES 
NO 
 
[INTERVIEWER, IF PARTICIPANT ASKS ABOUT STUDY RESULTS, YOU CAN MENTION 
THAT WE WILL BE SENDING PARTICIPANTS RESULTS AT THE END OF THE STUDY 
(LIKELY NOT UNTIL THE END OF [ADDRESS_242172])  
 
Thank you for your time.  We greatly  appreciate your participation in the study.  
 
[INTERVIEWER:  ENTER COMMENTS, CORRECTIONS, OR ANY OTHER RELEVANT 
INFORMATION ABOUT THE RESPONDENT] (varname  [CONTACT_203143]) ( varname  6 month:  
Comment6m ) 
 
 
 
 
 
IMPORTANT --AFTER EXITING INTERVIEW VERIFY CONTACT [CONTACT_203005] (FOR EXAMPLE, ADDRESS, PHONE 
NUMBERS)  
 
 
 
  
 
 
  
Protocol Version 2.0  Page 92 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6B.5: Barber Exit Interview  
 
Barber Exit Interview  
Study  ID: _____________    Barbershop: _____________________________ _ 
Below is a list of questions to determine your overall satisfaction in participating in the Nashville 
Implementation of the LA Barbershop Hypertension Study -Pi[INVESTIGATOR_4251]. We appreciate your 
participation and value your feedbac k. Please select one of the options per question as your 
answer. Thank you.  
Please choose one of the following:  Not at 
all A little 
bit Somewhat  Quite a 
bit Very 
much  
1. How satisfied were you working with the 
VUMC staff throughout the Nashville 
Barbershop study?  
 1 2 3 4 5 
2. Did you find that this study has brought 
positive community engagement to your 
barbershop?  
 1 2 3 4 5 
3. Do you feel that this study strengthened 
the relationship between you and your 
clientele?  
 1 2 3 4 5 
4. With the provided training, how confident 
were you as a Barber participating in the 
Nashville Barbershop study?  
 1 2 3 4 5 
5. Did you find that using the blood pressure 
machine interrupted your workflow 
providing haircuts?  
 1 2 3 4 5 
6. Did you find that using the blood pressure 
machine was bothersome?  
 1 2 3 4 5 
7. Overall, how satisfied were you 
participating in the Nashville Barbershop 
study?  
 [ADDRESS_242173] additional comments or further explanation of the questions above, please provide your 
response below:  
____________________________________________________________________________________
____________________________________________________________________________________
____________________________________________________________________________________
____ __________________________________________________ ______________________________  
 
 
  
Protocol Version 2.0  Page 93 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6C: Blood Pressure Information Card   
 
                                         â€œCut Your Pressure Tooâ€ Blood Pressure Card  
 
Participantâ€™s Name: ____________________________________________  
 
Your blood pressure on: _______________________ was /  
                                                              Date                                (Systolic/Diastolic)  
If your blood p ressure is:  
ïƒ¿ Below 120 / 80, it is within the normal range Please SEE A DOCTOR AT LEAST 
ONCE A YEAR TO MAINTAIN GOOD HEALTH.  
 
ïƒ¿ 120/80 - 139/89, it is in the high normal range Please SEE A DOCTOR WITHIN  
6 MONTHS.  
ïƒ¿ 140/90 - 159/99, it is elevated Please SEE A  DOCTOR WITHIN THE NEXT 1 MONTH.  
ïƒ¿ 160/100 â€” 179/109, it is very elevate d Please SEE A DOCTOR WITHIN THE NEXT  
2 WEEKS.  
 
ïƒ¿ 180/110 â€“ 199/119 or higher, it is extremely elevated Please SEE A DOCTOR  
WITHIN THE NEXT 3 DAYS.  
 
ïƒ¿ 200/[ADDRESS_242174] further questions,  
please call (615) [ADDRESS_242175] 
for information  on where to find a doctor.  
 
Thank you for participating in the Cut Your Pressure Too: The Nashville Barbershop  
Blood Pressure Study.  
 
        
Medical Director        Clinical Pharmacist  
Cut Your Pressure Too project -Nashville      
 

 
 
  
Protocol Version 2.0  Page 94 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6D: Templat e Pharmacist Note  
Patient Information  
Patient Name: ______ ______  ID #: ___ DOB: ____Patient Contact [CONTACT_5628]: phone ___ email: ___ 
Treating Physician: _______Physician Contact [CONTACT_7171]: phone:  _____ fax: ____email: ______  
Date of Todayâ€™s Visit: ______________    Appointment Start Time: ________  
Location of Todayâ€™s Visi t:  
â˜ Pharmacy â†’ Pharmacy Name_____________________________                        
â˜ Barbershop â†’ Location ___________________________________  
â˜ Otherâ†’ Location Name_____________________________________  
S/  
â˜ Patient reports tolerating antihypertensive medication well without side effects.  
â˜ Patient complains of experiencing an adverse drug reaction to antihypertensive 
medication.  
â˜ Patient complains of intolerance to antihypertensive medication regimen.  
â˜ Patient states there has been a significant interval change in health status.  
â˜ Other:  
 Comments:  
O/Medication Allergies:       
Medication  Reaction  Severity  
1)   
2)   
3)   
Current Medications:   
Medication  Dosage 
Form   Dose  Frequency  Date Last 
Filled  
1)     
2)     
3)     
4)     
5)     
6)     
7)     
8)     
9)     
10)     
Associated Medical Problems:  
â˜ DM 
â˜ CAD  
â˜ Stroke  
â˜ Heart Failure  
â˜ Hypercholesterolemia  
â˜ CKD  
â˜ Asthma / COPD  
â˜ Heart Block  
 
 
  
Protocol Version 2.0  Page 95 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   â˜ Other/Comments: Click here to enter text.  
Patientâ€™s BP in Barbershop on: Click here to enter a date.  Patientâ€™s BP today (only if no interval 
Barber -BP): 
 
BP 1   HR 1   
BP 2   HR 2   
BP 3   HR 3   
BP 4   HR 4   
BP 5   HR 5   
BP 6   HR 6   
BP 7   HR 7   
BP 8   HR 8   
Cuff Size:  
â˜ Medium  
â˜ Large  
â˜ Extra -large  
   
Labs on: Click here to enter a date.     Source of Labs:  â‘ POC or â‘ Laboratory  
Na  K  SCr  eGFR   Glu  
Targeted PE:  
Angioedema:   â‘ No  â‘ Yes                Gingival hyperplasia:  â‘ No  â‘ Yes 
Peripheral Edema  â‘ No  â‘ Yes    Skin Rash â‘ No  â‘ Yes 
A/ 
â˜ BP at goal at barbershop or today (if no interval barbershop BP); no changes in 
therapy warranted  
â˜ BP above goal at barbershop or today (if no interval barbershop BP); possible 
reasons for BP elevation include (check all that apply):  
 â˜ Patientâ€™s HTN is being undertreated   
 â˜ Patient prescribed non -protocol medication  
 â˜ Patient non -adherence  
 â˜ Other/Comments: Click here to enter text.  
Antihypertensive Medication -Related Problems Identified:  
â˜ Medication regimen not per protocol (not optimal based on current 
evidence/guidelines)  
â˜ Medication regimen insufficient to reach treatment goals (dose, interval, # of 
medications)  
â˜ Patient on short acting medication  
â˜ Contraindication  
â˜ Adverse Drug Reaction  
â˜ Drug interaction  
â˜ Drug therapy duplication  
â˜ Medication misuse/ poor adherence  
â˜ Abnormal lab result not addressed  BP 1   HR 1   
BP 2   HR 2   
BP 3   HR 3   
BP 4   HR 4   
BP 5   HR 5   
BP 6   HR 6   
BP 7   HR 7   
BP 8   HR 8   
 
 
  
Protocol Version 2.0  Page 97 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6E: Adverse Event Form  
 
PATIENT ID:  DATE FORM COMPLETED:  
HAS SUBJECT EXPERIENCED ANY ADVERSE 
EVENTS SINCE LAST VISIT?  ïƒ¿ YES 
ïƒ¿ NO 
 
 
 
 
 
 
 
IF YES, DESCRIPTION OF THE EVENT: 
_______________________________________________________  
EVENT ONSET DATE: _____/_____/_____  
  OR CHECK IF CONTINUING FROM LAST VISIT  
EVENT END DATE: _____/_____/_____  
  OR CHECK IF PRESENT AT THIS VISIT  
HAS PARTICIPANT GONE TO ER OR HOSPI[INVESTIGATOR_202907] T VISIT OR PHONE CALL?  ïƒ¿ YES 
ïƒ¿ NO 
IF YES, DESCRIPTION OF EVENT:  
REASON FOR HOSPI[INVESTIGATOR_55108]/ER VISIT: ___________________________________  
WHAT WAS THE DATE: _________________________________  
WHAT HOSPI[INVESTIGATOR_202908]: ________________________________  
 
DRUG  INTERVAL DRUG REACTIONS  
ïƒ¿ CCB (CALCIUM CHANNEL BLOCKER)  ïƒ¿ ANKLE EDEMA     ïƒ¿ HYPOTENSION  
ïƒ¿ BRADYCARDIA     ïƒ¿ GINGIVAL HYPERPLASIA  
ïƒ¿ ACE-INHIBITOR  ïƒ¿ COUGH                 ïƒ¿ ACUTE KIDNEY INJURY  
ïƒ¿ ANGIOEDEMA      ïƒ¿ HYPERKALEMIA  
ïƒ¿ ARB (ANGIOTENSIN RECEPTOR B LOCKER)  ïƒ¿ ALOPECIA            ïƒ¿ ACUTE KIDNEY INJURY  
ïƒ¿ THIAZIDE  ïƒ¿ ERECTILE DYSFUNCTION     ïƒ¿ GOUT  
ïƒ¿ HYPERGLYCEMIA                   ïƒ¿ HYPOKALEMIA  
ïƒ¿ HYPONATREMIA  
ïƒ¿ BETA BLOCKER  ïƒ¿ WHEEZING                               ïƒ¿ HEART BLOCK                   
ïƒ¿ ERECTILE DYSFUNCTION           
ïƒ¿ DEPRESSION  
ïƒ¿ ALPHA BLOCKER  ïƒ¿ DIZZINESS  
ïƒ¿ ANKLE EDEMA  
ïƒ¿ HEART FAILURE  
ïƒ¿ LOOP DIURETIC  ïƒ¿ ACUTE KIDNEY INJURY  
ïƒ¿ HYPOKALEMIA  
ïƒ¿ CLONIDINE (CENTRAL SYMP ATHOLYTIC)  ïƒ¿ REBOUND HYPERTENSION  
ïƒ¿ DRY MOUTH  
ïƒ¿ SOMNOLENCE  
ïƒ¿ DIRECT VASODILATORS  ïƒ¿ HEADACHE                            ïƒ¿ PALPI[INVESTIGATOR_202909]  
ïƒ¿ SHORTNESS OF BREATH           
ïƒ¿ LUPUS (hydralazine)             
ïƒ¿ PERICARDITIS (hydralazine)  
ïƒ¿ ALDOSTERONE BLOCKER  ïƒ¿ BREAST TENDERNESS/ ENLARGEMENT        ïƒ¿ 
HYPERKALEMIA       ïƒ¿ ACUTE KIDNEY INJURY  
ïƒ¿ ERECTILE DYSFUNCTION  
 
 
PHARMACIST SIGNATURE  [CONTACT_203144] 2.0  Page 98 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   SEVERITY GRADE (PLEASE CIRCLE ONE):  
1 = Grade 1: Mild AE (minor; no specific medical intervention; asymptomatic laboratory 
findings only, radiographic findings only; marginal clinical relevance)  
2 = Grade 2: Moderate AE (minimal intervention; local intervention; noninvasive intervention 
[packing, cautery])  
3 = Grade 3: Severe and undesirable AE (significant symptoms requiring hospi[INVESTIGATOR_188508]; transfusion; elective interven tional radiological procedure; therapeutic 
endoscopy or operation)  
4 = Grade 4: Life -threatening or disabling AE (complicated by [CONTACT_9420], life -threatening 
metabolic or cardiovascular complications such as circulatory failure, hemorrhage, sepsis. 
Life-threat ening physiologic consequences; need for intensive care or emergent invasive 
procedure; emergent interventional radiological procedure, therapeutic endoscopy or 
operation)  
5 = Grade 5: Fatal AE  
 
RELATIONSHIP TO STUDY DRUG (PLEASE CIRCLE ONE):  
1 = Probabl y Related . This category applies to those adverse events that are considered 
with a high degree of certainty to be related to the test drug.  
2= Possibly Related . This category applies to those adverse events for which a cause and 
effect relationship between the stu dy drug and the AE has not been previously demonstrated 
and it appears unlikely from the known effects of the drug but cannot be ruled out with 
certainty.  
3= Unlikely Related . In general, this category is applicable to adverse events that does not 
follow a reasonable temporal sequence related to drug administration or it is likely to be 
explained by [CONTACT_203012]; or t does not follow a pattern/manner known or suspected to be related to study 
drug  
 
EVENT PATTERN (PLEASE CIRCLE ONE):  
1 = Continuous  
2 = Intermittent  
3 = Unknown  
 
ACTION TAKEN WITH STUDY DRUG (PLEASE CIRCLE ONE):  
1 =   No action, continued on study drug without interruption  
2 =   No change, was not on study drug at the time of AE  
3 = Temporary discontinuation of study drug 4 = Permanently Discontinued of study drug  
 
HOSPI[INVESTIGATOR_202910] (PLEASE CIRCLE ONE):  
0 = No  
1 = Yes  
 
MEDICATIONS REQUIRED (PLEASE CIRCLE ONE):  
0 = No  
1 = Yes  
 
1/17/2012  
 
 
 
  
Protocol Version 2.0  Page 99 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6F: Example Study Pharmacist to Non -Study Physician Letters  
DATE  
 
Dear Dr.  NAME , 
As you know your patient, Mr. FIRST AND LAST NAME  [CONTACT_203145] [CONTACT_203013] a 
novel community -partnered approach to help control hypertension.  We are writing you today to 
inform you of your patien tâ€™s progress and to share forthcoming treatment recommendations with 
you.  
Unfortunately, Mr.  LAST NAME â€™s BP was not at goal and was most recently XXX/XX  when 
measured at his barbershop on DATE .   
The following changes were made to his medication regim en [EXAMPLE]:  
1. Amlodipi[INVESTIGATOR_050] 5 mg once daily was added   
2. Benazepril 10 mg once daily was increased to Benazepril 20 mg once daily  
His current medication regimen  is: 
1. Amlodipi[INVESTIGATOR_050] [ADDRESS_242176] NAME â€™s blood pressure on a monthly basis and report the 
readings to the study pharmacist, who will continue to work closely with Mr. LAST NAME  [CONTACT_203146] s participation in the project and will continually update you on his 
progress.   
Please do not hesitate to call us if you have any questions or concerns.  
Sincerely,  
 
 
 
 
 
 
   
Clinical Pharmacist  
Phone: XXX -XXX-XXXX  

 
 
  
Protocol Version 2.0  Page 100 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Date of Visit: XX/XX/XXXX  
Patient: FIRST AND LAST NAME , DOB: XX/XX/XXXX  
Treating Physician: Dr. LAST NAME  
[CONTACT_203147]: ADDRESS  
Associated Medical Problems: (i.e. Diabetes Mellitus Type II, Lupus)  
S:  This is a 41-year-old African American  man presenting for a first visit with study 
pharmacist in the Barbershop research study.  Mr. LAST  NAME  [CONTACT_203148] (Benazepril 10 mg once a day) well without side effects (denies 
cough, signs/symptoms of angioe dema).       
O: Patientâ€™s blood pressure in the barbershop (BP average of the final 3 of 5 BP readings):  
X/XX/XX  169/94  
X/XX/XX  152/88  
X/XX/XX  139/79  
 
BP Cuff Size: Medium  
Labs on DATE : 
A: 
Patientâ€™s antihypertensive medication regimen requires intensification and continued 
monitoring. Current antihypertensive regimen:  
 
P: 
Mr. LAST NAME  [CONTACT_203149][INVESTIGATOR_050] 5 mg once daily and increasing 
his benazepril dosa ge.  Unfortunately, Lotrel (amlodipi[INVESTIGATOR_050]/benazepril) is not covered by [CONTACT_203014].   
New Regimen (per study algorithm):  
Benazepril  20 mg daily  
Amlodipi[INVESTIGATOR_050]  5 mg daily  
 
Prescription called into PHARMACY (XXX -XXX-XXXX, spoke with Janet).  We will monitor Mr. 
LAST NAME â€™s BP and I will call him in a few days to see how he is tolerating his new 
medication regimen.  
Jane Doe, PharmD  
Clinical Pharmacist  
Phone: XXX-XXX-XXXX   Na 138 K 4.4 SCr 0.82 eGFR  127 Glu 209 
Benazepril  10 mg once 
daily 
 
 
  
Protocol Version 2.0  Page 101 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Appendix 6 G: Participant Treatment Report Example Template  
 

 
 
  
Protocol Version 2.0  Page 103 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   APPENDIX 7: DATA SAFETY MONITORING COMMITTEE PLAN/ SAE FORMS  
 
Preamble  
The monitoring  of SAE/U Ps is an important  process  for ensuring  the safety  of subjects  
participating  in clinical  research.  This document  establishes  a set of procedures  for collecting, 
evaluating, and  reporting SAE/UPs in  the study.  
  There will be two sources of safety data in this community -level intervention trial:  
(1) Research coordinators  will obtain patient -reported adverse events/unanticipated problems 
on emergency depart ment visits, hospi[INVESTIGATOR_602], death, and specific blood pressure 
medication sid e-effects at baseline, [ADDRESS_242177] data on interval changes in health.  
 
(2) The studyâ€™s Lead Clinical Pharmacist will obtain additional data on adverse events and 
unanticipated problems.  He/she will co llect data on patient -reported adverse events from 
monthly scheduled in -person or phone encounters plus additional follow up phone calls 
after every BP medication change. He/she also will collect safety data from Laboratory 
tests ordered when indicated dur ing the intervention period.        
Key Components of the Safety Monitoring Plan  
Definitions of Adverse Events and Unanticipated Problems are presented in Appendix 8. 
  
A flow diagram for expedited reporting of Serious Adverse Events/Serious Unanticipated 
Problems is presented in Appendix 9. A summary of the key components of the monitoring  
process  to be  undertaken  to detect and report SAE/UPs  for the study is  presented  below:  
1. The UCLA Data Coordinating Center (DCC):  The DCC  receives  submitted electronic 
reports  of AE/UPs  from research coordinators  and from the Lead Clinical Pharmacist . 
If AE/UP  is marked as serious on the electronic case report form and thus meets  the 
criteria  for expedited  reporting, an automatic e -mail notification is  sent immediately to 
both Physician Monitors and the PI; their roles are described later.   For non -serious 
AE/UPs, the  DCC will  provide blinded  quarterly safety  reports  to the DSMB,  and PI [INVESTIGATOR_202911] (Vanderbilt  University ). As the DCC only receives de -
identified information, th e local VUMC study team will link any collected data also in 
real time with the affected participant. This will be acted upon immediately as described 
here.  
 
2. Physician  Monitors:  The Physician  Monitors  serve  two major  roles  in the evaluation  of 
SAE/UPs  for the trial: 1) ongoing,  real-time reviews  of all individual  SAE/UP s from the 
research assistant or clinical pharmacist (VUMC) , review the medical records, make a 
rapid determination if the event indeed is serious and is related to research participation, 
and complete and forward to the PI [INVESTIGATOR_202912]/UPs shown in 
Appendix 12; and 2) monthly reviews  of cumul ative  SAE data to judge  whether there  are 
concerning  trends  in the occurrence  of event s. 
 
 
 
 
 
  
Protocol Version 2.0  Page 104 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   3. DSMB:  The DSMB  is responsible  for safeguarding  the interests  of study  participants  by 
[CONTACT_203015], and  by [CONTACT_203016].  The DSMB  reviews  the following  types  
of safety  data: 1) quarterly  reports from the UCLA DCC; 2) annual reports  from DSMB  
meetings;  and 3) expedited reports from the PI [INVESTIGATOR_202885]/UPs or concerning 
trends  identified  by [CONTACT_202964]. After reviewing  pertinent reports, the DSMB  
determines  whether  any trend  that may be identified  is related  to the trial. After each  
DSMB  meeting,  the study team will prepare a draft report for the DSMB Chair to review 
and sign. The VUMC PI [INVESTIGATOR_202913].  The report summarizes  the 
recommendations  of the DSMB  regarding  the safety  and continuance  of the study  and 
should be s ent to the PI [INVESTIGATOR_874] [ADDRESS_242178]  current  and potential  participants.  
 
4. PI: [INVESTIGATOR_202914]/UP, the PI [INVESTIGATOR_202915] 7 
days of its detection along with an appropriate plan to address it, if feasible. After 
each  scheduled  DSMB  meeting, the  PI [INVESTIGATOR_202916]  a summary report from the DSMB  
Chair  that summarizes  the DSMB  deliberations  and recommendations.  
 
Definition of Serious Adverse Events (SAEs) See also Appendix  8 
As defined  by [CONTACT_74379]  (http://www.nhlbi.nih.gov/crg/glossary.php#serious ), serious  adverse  
events  (SAEs)  are considered  to be those  events  that result  in at least one  of the following  
outcomes:  
1. Death  
2. Life-threatening  
3. Inpatient hospi[INVESTIGATOR_202917]  
4. Persistent or significant  disability/incapacity  
5. A congenital anomaly/birth  defect  
6. Other  events  that might jeopardize  the subject  and may require  medical or 
surgical  intervention  to prevent  one of the outcomes  listed  above  
 
Definition of Unanticipated Problems See Also  Appendix 8 
As specified  by [CONTACT_203017] (http://www.nhlbi.nih.gov/funding/policies/adverse.htm ) an 
unanticipated  problem (UP) is considered  to be  any event  or problem that  is: 
 
1. unexpected;  and 
2. possibly,  probably,  or definitely related  to study  participation;  and 
3. suggests  greater risk of harm to study  participant(s) than  was previously  
known  or recognized.  
 
An unanticipated  problem is classified as serious if the event  results in an emergency department 
visit, hospi[INVESTIGATOR_059], or death.  
 
 
 
 
 
  
Protocol Version 2.0  Page 105 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   Procedures for Reviewing and Reporting SAE/Ups  
The Study  personnel,  in previous  consultation  with NHLBI,  have  established  the following  
procedures  for reviewing  and reporting  SAE/UPs.  
1. Reporting of SAE/U PS by [CONTACT_079] (PI)  
The PI [INVESTIGATOR_202918]/UPs,  as described  below.  
2. Submission of the Case Report Form for SAE/Ups ( see Appendices 10-12) 
Adverse events forms will be electronically entered into the study database by [CONTACT_203018]. Pharmacist documents will also be maintained in the VUMC REDCa p study 
database . 
Detection and Initial Processing of SAE/Ups  
1. The electronic database is updated every 24 hours and is programmed to automatically 
send immediate e -mail notification of any new SAE/UP to both Physician Monitors and 
the PI. The report  contai ns all information  on the SAE/UP  that was entered  into the 
database.  
 
2. The DCC  Database Manager sends  summary cumulative  reports  of SAE/UPs  to the 
Physician  Monitors  monthly . The Physician  Monitor who has been assigned to that 
quarter reviews  the summary report to determine  if any concerning  trends  are noted.  
 
3. If a serious  problem  or trend  is suspected, the Physician  Monitors  would  request that 
the PI [INVESTIGATOR_202919].   
Physician Monitors  
 will serve  as Physician  Monitors  for this study.  If neither is 
available another study MD will be designated in their absence as needed.   as Cedars 
Sinai will also serve in this oversight role. The Physician  Monitors  are assigned  the responsibility  
of serving  as lead Physician  Monitor during  alternating  calendar quarters.  The Lead Physician 
Monitor completes the form but reviews it together with the other Physician Monitor. The 
Physician  Monitors  are given  limited  access  to the study  database  only to enter a Physician 
Monitor SAE/UP  Report Form  (see Appendix  12) for each  reported SAE/UP. The form serves  
as the monitorâ€™s  evaluation  of each  reported  SAE/UP. A description  of the process  for Physician  
Monitor  evaluation  of UPs/SAEs  is presented  below.  
 
1. The Physician  Monitor  evaluates  each  SAE/UP  to determine  if it is unexpected  and 
possibly,  probably,  or definitely  related  to the study  intervention,  and completes  the 
Physician Monitor SAE/UP  Report Form  (Appendix  12) online  within  three  (3) business  
days  of receipt.   Physician  Monitors use the  Comments  section  of the form when  
needed  to clarify  the context  or assumptions  used  in answering  form questions.  
 
2. If the participant went to the emergency department, was hospi[INVESTIGATOR_057], or died,  the 
Physician  Monitor  will need to request and review the medical  records. The Study 
Coordinator  will facilitate this process by [CONTACT_19201] a signed HIPAA waiver and request 
for release of medical records from the participant or his designee.  
 
 
 

 
 
  
Protocol Version 2.0  Page 106 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   3. The DCC Database Manager  prepares  quarterly  SAE/UP  reports  that include:  1) all 
SAE/UPs; 2) all SAE/UPs  related  to study participation;  and 3) a summary  of the SAE 
monitoring  process.  The monthly report  is emailed  to both Physician  Monitors, who 
review  the SAE/UP  reports  for any concerning trends.  Should  any concerns  arise due 
to observed  trends, the lead Physician  Monitor for that quarter  sends  a written  
recommendation  to the PI [INVESTIGATOR_202920].  
 
Procedure for Expedited Reporting of SAE/Ups (see Appendix 9) 
1. Expedited  SAE/UP  reports  from the PI [INVESTIGATOR_202921]:  
â–ª Study  title, grant  number,  PI [CONTACT_2300]  
â–ª Description  and date of the event  or problem, including  why it merits  
expedited  reporting  
â–ª When  it becomes  available,  date(s)  on which  the SAE/UP  was detected by 
[CONTACT_181106] e -mail alerts sent to the Physician Monitors and PI, and the 
date on which the PI [INVESTIGATOR_202922] , and applicable  
oversight  bodies  (relevant  IRBs, the DSMB,  Office  for Human  Research  
Protections).  
â–ª Any corrective  action  planned  or taken  in response  to the SAE/UP  (e.g.,  
study  suspension,  consent or protocol  changes, additional training  or 
security  measures).   
â–ª Signature  [CONTACT_136269] 
 
2. All communications  from the relevant  oversight bodies  regarding  any expedited  
UP/SAE  must  be reported  to NCATS . 
 
3. The PI [INVESTIGATOR_202923]/SAEs  to the 
DSMB,  as noted  above.  
 
Quarterly Reporting of SAE/Ups to the DSMB  
Each  quarter, the study  biostatistician  sends  cumulative  summary tables  of all SAEs,  all 
related  SAE/UPs to the DSMB.   
Interim Monitoring Plan  
There  will be no interim  analyses  for futility.  
SAE/UPs Reports  
Each  quarter , the UCLA DCC prepares  cumulative  SAE/UPs  reports  for review  by [CONTACT_203019].  Cumulative  SAE/UPs  reports  are transmitted  to the DSMB  for review  each  quarter,  
and cumulative  summary  reports  are prepared  for each  teleconference  or in-person  closed 
session  meeting  of the DSMB.  
 
SAE/UP tables  are included  in the monthly cumulative  reports from the DCC to the Physician  
Monitors:  
â–ª Summary data on all SAE/UPs  
â–ª Summary of SAE/UPs Related to the Research   
â–ª Summary  of Serious  Adverse  Event  Monitoring  Process  
â–ª Listing of individual SAE/UPs   
 
 
 
 
  
Protocol Version 2.0  Page 107 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   APPENDIX [ADDRESS_242179]  medical occurrence  associated  with the use of a drug in 
humans, whether  or not considered  drug related.  An adverse  event (also  referred  to as  an 
adverse  experience)  can also be any unfavorable  and unintended  sign (e.g.,  an abnormal  
laboratory  finding),  symptom,  or disease  temporally  associated  with the use of a drug, without  
any judgment  about  causality.  An adverse  event can arise  from any use of a drug (e.g.,  off label 
use, use in combination  with another  drug) and  from any route  of administration,  formulation  or 
dose,  including  overdose.  
 
Serious  Adverse  Event  (SAE ) â€“ An adverse  event  or suspected  adverse  reaction  is considered  
"serious" if, in the view of either the investigator  or sponsor, it results  in any of the following  
outcomes:  Death, a life-threatening  adverse  reaction,  inpatient  hospi[INVESTIGATOR_56901],  a persistent  or significant incapacity  or substantial  disruption  of the 
ability  to conduct normal life  functions,  or a congenital anomaly/birth  defect.  Important medical 
events  that may not result  in death, be life-threatening,  or require  hospi[INVESTIGATOR_202924], based  upon  appropriate  medical judgment,  they may jeopardize  the 
patient  or subject  and may require  medical or surgical intervention  to prevent  one of the 
outcomes  listed  above.  
 
Unanticipated  Problem  - any incident,  experience,  or outcome  that meets  all of the following  
criteria: 1) unexpected  2) related  or possibly  related  to participation  in the research;  and 3) 
suggests  that the research  places  subjects  or others  at a greater risk of harm than  was 
previously  known  or recognized.  
 
OHRP  considers  unanticipated  problems , in general,  to include  any incident,  experience,  or 
outcome  that meets  all of the following  criteria:  
(1) unexpected  (in terms  of nature,  severity,  or frequency)  given  (a) the research  procedures  
that are described  in the  protocol -related  documents,  such  as the IRB- approved  research  
protocol and  informed  consent  document; and  (b) the characteristics  of the subject 
population  being  studied;  
 
(2) related  or possibly  related  to participation  in the research  (in this guidance  document,  
possibly  related means  there  is a reasonable  possibility  that the incident,  experience,  or 
outcome  may have  been caused  by [CONTACT_157605]);  and 
 
(3) suggests  that the research  places  subjects  or others  at a greater risk of harm  (including  
physical,  psychological,  economic, or social harm) than  was previously  known  or recognized.  
 
 
  
Protocol Version 2.0 Page 108 of112 CONFIDENTIAL 
Protocol Date: 02_2 5_2020APPENDIX 9FLOW DIAGRAM FOR EXPEDITED REPORTING OF SERIOUS ADVERSE
EVENTS AND SERIOUS UNANTICIPATED PROBLEMS (SAE/UP)

 
 
  
Protocol Version 2.0  Page 109 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   APPENDIX 10 RESEARCH ASSISTANT  AE/UP  FORM  
(Completed at Baseline and 3, 6 -month follow up  â€“ embedded within those forms also)  
Interviewer/ Research Assistant  AE/UP Form  
1. In the past [ADDRESS_242180] you gone to the Emergency Room or been hospi[INVESTIGATOR_057]?  
a. Yes 
b. No 
 
2. If yes to #1, please ask the following questions:  
a.  For what reason were you hospi[INVESTIGATOR_202925]? 
____________________  
b. What date were you in the hospi[INVESTIGATOR_202902]?  ___/____/____  
c. What hospi[INVESTIGATOR_202903]? _____________________  
 
3. In the past [ADDRESS_242181] you experienced any of the following? (check all that apply)  
â–¡ swollen ankles  
â–¡ swollen gums  
â–¡ swelling of the lips, throat, and/or tongue  
â–¡ hair loss  
â–¡ erectile dysfunction  
â–¡ gout  
â–¡ difficulty breathing or wheezing  
â–¡ dry cough  
â–¡ depression  
â–¡ headache  
â–¡ palpi[INVESTIGATOR_814] (feeling that your heart is pounding or racing)  
â–¡ breast tenderness or enlargement  
â–¡ excessive sleepi[INVESTIGATOR_202904]  
â–¡ dizziness  
â–¡ skin rash  
 
4. If yes for any #3, rate severity: How severe was the reaction?  
â–¡ Mild (I did not need to see my do ctor about the reaction)  
â–¡ Moderate (I needed to see my doctor about the reaction)  
â–¡ Severe (I was hospi[INVESTIGATOR_057])  
â–¡ Life -threatening (I was hospi[INVESTIGATOR_202905] (ICU)  
 
 
 
  
 
 
  
Protocol Version 2.0  Page 110 of 112 CONFIDENTIAL  
Protocol Date: 02_2 5_2020   APPENDIX  [ADDRESS_242182]  AE/UP  FORM â€“ SEE APPENDIX 6E
 
Protocol Version 2.0  Page 111 of 112   CONFIDENTIAL  
Protocol Date: 02_2 5_2020  
 APPENDIX  12 PHYSICIAN MONITOR SAE/UP REPORT FORM  
 
Physician Monitor Report of a SAE/UP  
 
1. Date of SAE: __ __/__ __/__ __ __ __ (mm/dd/yyyy)  
 
2. Date site became aware of SAE: __ __/__ __/__ __ __ __ (mm/dd/yyyy)  
 
3. Description of SAE:  _____________________________________________________  
 
4. Check the outcomes that are attributed to the SAE in the medical record or reported by [CONTACT_1560] (c heck all that apply ):  
ïƒ¿ a. Death  
a.1 Death Date: __ __/__ __/__ __ __ __ (mm/dd/yyyy)  
 
ïƒ¿ b. Life -threatening condition  
 
ïƒ¿ c. Hospi[INVESTIGATOR_059] â€“ initial or prolonged  
 
ïƒ¿ d. Disability  
 
ïƒ¿ e. Congenital anomaly  
 
ïƒ¿ f. Required intervention to prevent permanent impairment/damage  
 
Option 4.f should be used for an event that does not result in death, a life -threatening 
condition, hospi[INVESTIGATOR_059], disability or congenital deformity, but that did jeopardize the 
subject and that required a specific medical intervention to prevent one or  more of 
outcomes 4.a â€“ 4.e from occurring.  
 
ïƒ¿ g. Important medical event as determined by [CONTACT_7880] [INVESTIGATOR_202926] 4.g should only be chosen when a site judges the event to represent significant 
hazard or harm to a research subject.  
OR  
 
ïƒ¿ h. No ne of the above  
 
 
 
 
 
 
 
 *** If you checked one or more of items 4.a â€“ 4.g, continue to complete the remaining sections.  
 
If you checked 4h (None of the above) , this is not a serious event. You do not need to complete the rest 
of this form.   
 
 
  
Protocol Version 2.0  Page 112 of 112   CONFIDENTIAL  
Protocol Date: 02_2 5_2020  
 6. Was the SAE an exacerbation of a pre -existing condition (i.e. existing prior to enrollment)?  
ïƒ¿ Yes   ïƒ¿  No  
 
7. Was the SAE related or might it have been related to an antihypertensive medicati on?  
ïƒ¿ Yes   ïƒ¿  No  
 
If yes, please list the medication(s) that might have been related to the event:  
 
 Medication:  Stopped because of Adverse Event?  
 
a. _______________________  
 ïƒ¿ Yes    
ïƒ¿  No  
 
b. _______________________  
 ïƒ¿ Yes    
ïƒ¿  No  
 
c. _______________________  
 ïƒ¿ Yes    
ïƒ¿  No  
 
8. Do you believe the SAE was unexpected in terms of severity or frequency?  
ïƒ¿ Yes   ïƒ¿  No  
 
If yes, why? 
________________________________________________________________________  
 
9. Do you believe the SAE was possibly related to participation in the research?  
ïƒ¿ Yes   ïƒ¿  No  
 
If yes, why? 
________________________________________________________________________  
 
10.  Do you believe the SAE suggests that the research places subjects or others at greater risk 
of harm than was previously known or recognized?  
ïƒ¿ Yes   ïƒ¿  No  
 
If yes, why? 
_______ ________________________________________________________________ __ 
 
11. Describe relevant scans/tests/laboratory data related to the SAE, including dates.  
 
 
12. Describe other relevant history, including pre -existing medical conditions (e.g. 
allergies, smoking and alcohol use, hepatic/renal dysfunction) . 
_________________________________________________________________________  
 
 